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1. Introduction
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are
sequence-selective DNA minor-groove binding agents based
on the naturally occurring anthramycin family of antitumor
antibiotics,[1] the best known member of which is anthramycin
itself (1, Figure 1) which was isolated from Streptomyces
refuineus in 1965.[2] The skeletal structure of the PBDs
contains a substituted aromatic A-ring, a diazepine B-ring and
a pyrrolidine C-ring, with an S-chiral center at the C11a-
position between the B and C rings. This provides a 3-
dimensional shape perfectly crafted for the molecules to fit
within the DNA minor groove (Figure 2). They also possess
an electrophilic imine moiety (or equivalent carbinolamine or
carbinolamine methyl ether) at the N10–C11 position within
their B-ring which can form a covalent aminal linkage
between their C11 carbon and the C2-NH2 group of a guanine
base (Figure 2A), but only after the molecule is secure within
the minor groove (Figure 2B). PBD monomers such as
anthramycin (1) typically span three DNA base pairs with
a reported preference for 5’-Pu-G-Pu-3’ sequences,[1b,3]
although more recent data suggest that they have a kinetic
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the biology of PBDs, and the strategies for their use as payloads for
ADCs.
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Figure 1. Structures of the naturally occurring anthramycin (1), the
PBD C8-conjugates GWL-78 (2) and KMR-28–39 (3), and examples of
C7/C7’-linked (4) and C8/C8’-linked (e.g., DSB-120, 5a, n=3 and SJG-
136, 6a, n=3) PBD Dimers.
[*] Dr. J. Mantaj,[+] Dr. P. J. M. Jackson,[+] Dr. K. M. Rahman
Institute of Pharmaceutical Science, King’s College London
Britannia House, 7 Trinity Street, London SE1 1DB, and Femtogenix
Ltd, Britannia House, 7 Trinity Street, London SE1 1DB (UK)
Prof. D. E. Thurston
Professor of Drug Discovery, King’s College London, Faculty of Life
Sciences & Medicine, Institute of Pharmaceutical Science
Britannia House, 7 Trinity Street, London SE1 1DB (UK)
and
Femtogenix Ltd, Britannia House, 7 Trinity Street, London SE1 1DB
(UK)
E-mail: david.thurston@kcl.ac.uk
[+] These authors contributed equally to this review.
The ORCID identification number(s) for the author(s) of this article
can be found under http://dx.doi.org/10.1002/anie.201510610.
 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co.
KGaA. This is an open access article under the terms of the Creative
Commons Attribution Non-Commercial NoDerivs License, which
permits use and distribution in any medium, provided the original
work is properly cited, the use is non-commercial, and no
modifications or adaptations are made.
Angewandte
ChemieReviews
&&&&Angew. Chem. Int. Ed. 2016, 55, 2 – 29  2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
These are not the final page numbers! 
preference for 5’-Py-G-Py-3’ sequences (Pu= purine, Py=
pyrimidine).[4]
Since the discovery of anthramycin in the early 1960s[2]
and its subsequent evaluation in the clinic,[5] a range of
synthetic PBDs[1f, 6] has been developed by various academic
groups and industrial laboratories. For example, non-covalent
minor-groove binding components have been appended to
the C8-position of the PBD A-ring (e.g., GWL-78[3a] (2) and
KMR-28–39[7] (3), Figure 1), and monomeric PBD units have
been joined together through their C7/C7’-[8] (4) and C8/C8’-
positions (e.g., 5a–d and 6a,b) to afford PBD dimers (e.g.,
DSB-120[9] (5a) and SJG-136[10] (6a), Figure 1). PBD units
have also been joined through their C8/C2’- and C2/C2’-
positions but the resulting dimers do not have the appropriate
shape to fit into the DNA minor groove, and so have poor
DNA-binding affinity and cytotoxicity (see Figure 6).[11] C2/
C8’-linked triazolo PBD dimers, connected using a click
chemistry approach, have a similarly poor DNA-binding
profile.[12] The unique structure of the PBD dimers which
contain two alkylating imine functionalities allows them to
form interstrand or intrastrandDNA cross-links in addition to
mono-alkylated adducts,[14] thus resulting in greater DNA
stabilization[10,15] compared to monomeric PBDs. Due to the
additional types of DNA adducts possible and the greater
adduct stability, the C8-linked PBD dimers generally have
significantly greater cytotoxicity,[9] antitumor activity[16] and
antibacterial activity[17] compared to PBDmonomers, and one
such agent, SJG-136, has reached Phase II clinical trials in
ovarian cancer and leukaemia.[18] Furthermore, related PBD
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Figure 2. A) The mechanism of covalent binding of a PBD to DNA
once it has located in a low-energy position within the minor groove.
B) Molecular model of the crystal structure of anthramycin (PDB ID
274D)[13] covalently bound to G19 (magenta) of the sequence 5’-
CC(G)AACGTTGG-3’ (covalently modified guanine underlined and in
brackets as it on the opposing DNA strand) as an example of a PBD–
DNA adduct. Due to the perfect fit of anthramycin in the DNA minor
groove (as a consequence of its 3-dimensional shape created by the
C11a(S) chiral center), normal base-pairing is maintained (cyan) with
negligible distortion of the minor groove.
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dimers are now being used as payloads for antibody–drug
conjugates (ADCs) due to their significant cytotoxicity.[19] The
covalent binding of both monomeric and dimeric PBDs to
DNA is thought to be a two-step process, the first involving
recognition of a favored low-energy binding site by fast,
reversible non-covalent association of the molecules in the
minor groove through interactions including hydrogen bond-
ing, van der Waals and electrostatic contacts. If these non-
covalent intermolecular interactions are weak, the PBD
presumably dissociates and re-associates at another site,
with this process repeating itself until an appropriate low-
energy site is found containing one or two guanine C2-NH2
groups (for PBD monomers or dimers, respectively) suitably
aligned for nucleophilic attack at the PBD C11-position(s). In
the second step, the PBD forms one or two covalent bonds
with the guanine base(s), and the molecule is then locked into
position. Whereas the initial non-covalent association is a fast
process, the covalent attachment step is variable in rate
depending on the PBD structure and DNA sequence, and can
take between 3[4] to 24[14] hours to complete (Figure 2A).
Once covalently bound to DNA, PBD monomers and
dimers have been shown to mediate a number of biological
effects in cells including DNA strand breakage,[20] inhibition
of DNA processing enzymes (e.g., endonuclease BamH1,[21]
RNA polymerase[3a,22] and Ligase 1[23]) and specific tran-
scription factors (e.g., Sp1,[24] NF-Y[25] and NF-kB),[25a,26] and
modulation of various signaling pathways (e.g., p53-depen-
dent and -independent apoptogenic,[27] JNK/AP-1,[8] VEGF[28]
and SDF1a[28] signaling). Many of these proteins and signaling
pathways are upregulated in tumor cells compared to healthy
cells which could, in part, explain the anticancer activity of the
PBDs in animal models and humans.[3c]
2. Structure–Activity Relationships of PBDs
Since their discovery in the 1960s, a substantial body of
structure–activity relationship (SAR) data has been gener-
ated based on both the known PBD natural products and the
large number of synthetic analogues that have become
available. A summary of the key SAR features of PBD
monomers (Figure 3A) and dimers (Figure 3B), and of their
structural analogues, the indolinobenzodiazepine dimers
(Figure 3C), is provided below.
2.1. N10–C11 Imine (or Equivalent)
The presence of an imine, carbinolamine or carbinolamine
methyl ether group at the N10–C11 position is essential for
covalent interaction of a PBD molecule with DNA. Early
studies by Kohn[29] and Hurley[30] demonstrated that PBDs
covalently bind to guanine-containing DNA sequences, and
also established that they do not interact through an
intercalation mechanism[29b] (Figure 2).
Crucially, replacement of the N10–C11 imine with lactam
(Figure 4A) or secondary amine (Figure 4B) functionalities
results in a dramatic reduction in DNA-binding ability[31] and
cytotoxicity. For example, the loss of DNA-binding affinity
upon replacing the two N10–C11 imine functionalities of the
PBD dimer SJG-136 (6a) with lactams has been demon-
strated.[10] Similarly, didehydroanhydroanthramycin[32] (Fig-
ure 4C) which has extended N10–C11/C11a–C1/C2–C3 con-
jugation is biologically inactive, as the N10–C11 imine is too
stable to react with a guanine base. Although PBD dilactams
(e.g., Figure 4A) cannot bind covalently to DNA, they are
still isohelical with the DNA minor groove due to their chiral
C11a-position, and so can possess weak DNA-binding proper-
ties through non-covalent hydrogen bonding and other
Figure 3. Summary of structure–activity relationships (SARs) for A) the PBD monomers, B) the PBD dimers, and C) the indolinobenzodiazepine
analogues. Modifications which enhance activity are shown in blue, and those which reduce activity in red.
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interactions such as van der Waals. For example, a series of
dilactams synthesized by Lown and co-workers[33] provided
a thermal stabilization (i.e., DTm) of up to approximately 3 8C
with calf thymus DNA, although this compares unfavorably
with a simple PBD monomer such as anthramycin which
provides a DTm of 13.1 8C under the same conditions. PBD
dimers produce significantly higher DTm values compared to
monomers due to their length (and hence greater number of
non-covalent contacts in the minor groove) and cross-linking
ability.[15] Libraries of PBD dilactams synthesized by Thurston
and co-workers have shown similar DTm ranges (e.g., up to
approximately 2.4 8C for C2-aryl substituted dilactams)[31a] to
those reported by Lown and co-workers.[33a]
2.2. C11a/C11 Stereochemistry
It has been shown through NMR[34] and X-ray crystallog-
raphy[13] studies that all naturally occurring PBDs exist in
a single stereochemical form (i.e., S) at their C11a-position
which provides the right-handed twist that allows the
molecules to follow the curvature of the minor groove
within the right-handed B-DNA helix. Molecules with the
(R)-stereochemistry at C11a are not isohelical with the DNA
minor groove, causing them to sterically clash with the groove
wall.[13,35] Examples of PBDs with the incorrect (R)-stereo-
chemistry at C11a have been synthesized and, as predicted, do
not possess significant DNA-binding affinity or cytotoxic-
ity.[36] Although PBDs themselves can exist as imines at their
N10–C11 position, or carbinolamines or carbinolamine
methyl ethers with different stereochemistry at their C11-
position, there are conflicting reports in the literature as to
the stereochemistry at the C11-position of a PBD molecule
once bound to DNA. Although an anthramycin–DNA crystal
structure[13] and a number of NMR studies of both PBD
monomers[34,35] and dimers[37] bound to DNA have shown that
the adduct formed is in the C11(S)-configuration, molecular
mechanics calculations[38] and one NMR-determined struc-
ture[39] suggest that, in some situations, both R- and S-
configurations are equally preferred. It is now thought that
PBD monomers can form either R- or S-adducts at C11, and
that the outcome may depend on the substitution pattern of
a particular PBD (e.g., C8-substitution may be partially
influential) and the DNA sequence to which it is covalently
bound.[38c]
2.3. Functionalization of the A-Ring
The number and pattern of substituents in the A-ring of
the PBD skeleton can affect the DNA binding ability and
cytotoxicity. The presence of electron-donating substituents,
particularly at the C7- and C8-positions, can enhance DNA
interactivity by increasing the electrophilicity (through
enhanced ability of the N10-atom to protonate) and alkylat-
ing potential of the N10–C11 imine moiety.[40] Furthermore,
extensive molecular modeling studies have shown that C8-
substituents can position themselves along the floor of the
minor groove leading to significant additional stabilization of
the adduct.[7] Thus heterocyclic fragments (e.g., pyrroles,
furans, imidazoles, thiophenes, indoles, benzofurans and
biaryl units) have been added to this position to create PBD
C8-conjugates[3a,7, 25b,28,41] (e.g., GWL-78,[3a] KMR-28-39,[7]
Figure 1). Similarly, two PBD units have been joined through
their C8-positions to create C8/C8’-linked PBD
dimers,[10,37a,42] and this approach led to the design and
synthesis of the C8/C8’-linked PBD dimer SJG-136[43]
(Figure 1). The C7-position has also been used as a potential
linking point for PBD dimers,[8a] but molecules joined in this
way have significantly less DNA cross-linking potential and
cytotoxicity, as the two PBD units are not properly aligned for
alkylation of guanine bases.[8b] Based on experiments with
anthramycin in mice and rats, the presence of a hydroxy group
at C9 is thought to render a PBD cardiotoxic due to free
radical production which can damage cardiac tissue.[5] Other
studies on PBDs such as anthramycin[13] have suggested that
a C9-OH group has the potential to hydrogen bond to bases
within the minor groove of DNA, thus increasing binding
affinity and influencing sequence selectivity.[13] The presence
of a larger group (e.g., a methoxy group) at C9 appears to
render the PBD biologically inactive[44] potentially due to
steric hindrance between this substituent and functional
groups on the minor groove floor, as can be demonstrated
through molecular dynamics simulations.[45]
2.4. C-Ring Unsaturation
The degree of unsaturation associated with the C-ring of
a PBD can also influence its DNA-binding ability and
cytotoxicity. In general, PBD monomers with C2-exo or C2-
endo unsaturation (e.g., anthramycin,[30] tomaymycin[46] and
sibiromycin)[47] have enhanced DNA-binding affinity relative
to PBD monomers with fully saturated C-rings (e.g., neo-
thramycin A,[48] chicamycin[49] and DC-81).[1a] This feature has
been adopted in the rational design of PBD dimers (see
Figure 4. Structures of PBD analogues in which the electrophilic N10–
C11 imine moiety has been replaced with a lactam (i.e., dilactam, A)
or a secondary amine (B), or in which the imine has been rendered
non-electrophilic by conjugation with double bonds in the C-ring to
create a fully aromatized system (i.e., didehydroanhydroanthramycin,
C). All molecules of types A, B and C cannot bond covalently to DNA,
and so have negligible cytotoxicity. Some examples (e.g., dilactams of
type A) can still bind to DNA, albeit weakly, through non-covalent
interactions because they still have the appropriate 3-dimensional
shape to fit into the DNA minor groove.[31a]
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Figures 3B and 3C), where introduction of exo-unsaturation
at the C2/C2’-positions of the PBD dimer DSB-120[37a] (5a,
Figure 1) led to SJG-136 (6a, Figure 1). DSB-120 has poor
activity in vivo, attributed partly to its high reactivity with
cellular thiol-containing molecules such as glutathione.[50]
However, introduction of C2/C2’-exo unsaturation as in
SJG-136 led to an overall increase in DNA-binding affinity
and cytotoxicity, and a lower reactivity toward cellular
nucleophiles with more of the agent potentially reaching its
target DNA. Modeling studies have shown that C2/C2’-
unsaturation causes a flattening of the C-ring which may lead
to superior van der Waal contacts within the minor groove[10]
thus contributing to the enhanced DNA-binding affinity.[38a]
Interestingly, complete unsaturation of the C-ring signifi-
cantly reduces the electrophilicity of the N10–C11 imine by
producing a fully aromatic system across the N10–C11/C11a–
C1/C2–C3 positions which ablates DNA-binding ability and
cytotoxicity (e.g., didehydroanhydroanthramycin,[32] Fig-
ure 4C).
2.5. C-Ring Substitution
In a similar manner to C9-substitution, a substituent at C3
can affect the activity of a PBD. For example, methylation of
the C3-hydroxy substituent of neothramycin A reduces
cytotoxicity relative to unsubstituted neothramycin.[51] How-
ever, extended C2-substituents (e.g., the conjugated acrylam-
ide side chain of anthramycin)[13] significantly enhance DNA
interactivity because they locate along the minor groove and
stabilize the adduct through van der Waals interactions and
sequence-specific hydrogen bonds to functional groups in the
minor groove floor. For example, early studies on anthramy-
cin suggested that removal of the C2-acrylamide side-chain
significantly reduced its DNA-interactivity.[44,52] This knowl-
edge of SAR at the C2-position has been used to design novel
C2-substituted PBD monomers and dimers with enhanced
DNA-binding ability and cytotoxicity.[19,31a] For example,
some C2-substituents (e.g., p-tolyl) can lead to cytotoxicities
in the low nanomolar range.[31a] Studies have also shown that
replacement of the C1-atom itself with an oxygen can provide
analogues (e.g., oxazolobenzodiazepines) with similar activity
to the parent PBDs.[53] C1-substituted PBD monomeric
conjugates have also been synthesized recently, and shown
to have cytotoxicity in the nanomolar range.[54] Molecular
modeling studies have shown that the C1-polyamide sub-
stituents locate in the minor groove and generate additional
hydrogen bonding and other interactions, thus enhancing
DNA-binding affinity and cytotoxicity.[54]
2.6. Other Modifications
Many of the modifications outlined above have been
incorporated into PBD dimers that are now being used as
chemical payloads for ADCs (Figure 3B,C). For example, the
ADC SGN-CD33A (Vadastuximab talirine) produced by
Seattle Genetics Inc. (see Section 5) contains a C2–C3/C2’–
C3’-endo-unsaturated C2/C2’-bis-aryl PBD with a C8/C8’-
propylenedioxy linker, and another PBD-based ADC Roval-
pituzumab tesirine (“Rova-T”) produced by Stemcentrx Inc.
contains a PBD dimer with C2–C3/C2’–C3’-endo-unsaturated
C2/C2’-bis-methyl substitutions. In the case of both ADCs,
the A-rings contain oxygen substituents in both the C7- and
C8-positions which enhance interactivity with DNA, but the
C9-position remains unsubstituted, thereby minimizing any
steric interactions within the minor groove. However, in
addition, researchers at Sanofi S.A. and ImmunoGen Inc.
have introduced a fourth D-ring to the C-ring of the PBD
skeleton to produce indolinobenzodiazepines (Figure 3C).
They have also introduced an aromatic ring into the center of
the C8/C8’-linker which is thought to enhance DNA-binding
affinity and provides an antibody attachment point (Fig-
ure 3C).
3. Evolution of the PBD Dimers
The first PBD dimers were synthesized by Suggs and co-
workers in 1988[8] with the two PBD units joined through
linkers attached at the C7/C7’-positions of the aromatic A-
rings (4a–c, Figure 1). Although modest DNA cross-linking
activity was reported, no cytotoxicity data were disclosed.
Based on a rational approach to the way in which a PBD
dimer might best fit into the DNA minor groove, in 1992
Thurston and co-workers[9] reported the PBD dimer DSB-120
(5a, Figure 1) which consists of two unsubstituted PBD units
coupled through their C8/C8’-positions via a 1,3-dioxypropyl
linker. This molecule, which was designed to more closely
follow the curvature of the minor groove, had a very high
stabilizing effect on calf thymus DNA (i.e., DTm > 15.1 8C),
significant interstrand cross-linking activity toward linear
pBR322 plasmid DNA (i.e., > 90% cross-linking for 0.4 mm
drug concentration at 1:1 DSB-120/DNA), and sub-micro-
molar cellular cytotoxicity in some tumor cell lines (e.g.,
lymphosarcoma ADJ/PC6).[9] SAR studies[55] demonstrated
that changing the central methylene linker from 3 (5a) to 4, 5
or 6 methylene units (5b–d) still allowed DNA binding but
significant differences in binding affinity were observed.
Increasing the linker length to n= 5 (5c) afforded a molecule
with similar cross-linking activity to DSB-120 (n= 3) but with
approximately half of the DNA stabilizing ability, while the
cellular cytotoxicity was significantly enhanced. However,
increasing the linker length to n= 4 or 6 afforded a reduction
in all three parameters, and led to the conclusion that linkers
with an odd number of methylenes are preferred for
maximum cytotoxicity. This was later explained through
molecular modeling studies,[55] as only dimers with odd
numbers of methylenes in their C8/C8’-linkers allow the two
PBD units to arrange themselves in the correct orientations
for their N10–C11 imine moieties to alkylate guanine C2-NH2
groups. Although DSB-120 had potent activity in biophysical
and cellular assays, it proved to be inactive in human tumor
xenograft studies in mouse models. This was thought to be
due to the N10–C11 imine moieties being too electrophilic
due to the fully saturated state of the C-rings, leading to the
molecule reacting with extra- and intra-cellular thiol-contain-
ing nucleophiles before it could reach its DNA target.[50,56]
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The addition of methylene substituents to the C2/C2’-
positions to afford SJG-136 (6a, Figure 1)[10] appeared to
reduce the electrophilicity of the N10–C11 imine moieties,
increasing the potential for the molecule to reach its target
DNA in the nucleus of cells. This was attributed to flattening
of the C-rings due to the presence of the C2/C2’-exo-
methylene substituents which appear to modify the electro-
philicity of the N10–C11 imines through an, as yet, unidenti-
fied mechanism, and also provide a better fit of the molecule
in the minor groove. This analogue was not only more potent
in biophysical and cellular assays but was also active in vivo in
human tumor xenograft mouse models.[16,57] Due to the
presence of two electrophilic imine moieties, SJG-136 (6a)
can form interstrand and intrastrand DNA cross-links in
addition to monoalkylated adducts (Figure 5).[10,58] The type
of adducts that form appears to depend on both the precise
DNA sequence and the distance between reacting gua-
nines.[14,59] Although earlier studies suggested that SJG-136
(6a) formed only Pu-GATC-Py interstrand cross-linked
adducts,[1i, 60] more recent HPLC-MS studies have established
that it can also form intrastrand cross-links at longer Pu-
GAATG-Py sequences for which, in some cases, it can have
a preference, and mono-adducts.[14]
Examples also exist in the literature of PBD dimers linked
through their C8/C2’-[11a] or C2/C2’-positions[11b] rather than
their C8/C8’-positions (Figure 6), but these are at least 103-
fold less cytotoxic than the most potent C8/C8’-linked dimers.
For example, Thurston and co-workers[11a] synthesized a C8/
C2’-linked PBD dimer (Figure 6A) containing C2’/C3’-endo
unsaturation at the C2-linkage, which had an IC50 of > 25 mm
in A2780 cells. This is less cytotoxic than the C2-unsubstiuted
PBD monomer DC-81, suggesting that the second PBD unit
may be impeding rather than enhancing DNA-interaction.
Kamal and co-workers[61] synthesized two similar C8/C2’-
linked dimers consisting of a C8’-benzyloxy-PBD linked via
an exocyclic double bond at the C2’-position to the C8 of
a second PBD unit (Figure 6B; n= 1 or 2). The most potent
dimer (n= 1) had cytotoxicity in the micromolar range (e.g.,
2.6 mm in the MCF-7 cell line), and in DNA thermal
denaturation studies gave a DTm of 5.7 8C after incubation
with calf thymus DNA for 18 hours. This compared unfavor-
ably with the DTm for the C8/C8’-linked dimer DSB-120
under similar conditions (i.e., 15.1 8C), again suggesting
a poor fit in the DNA minor groove. In the same study,
Kamal and co-workers synthesized other C8/C2’-coupled
analogues in which one of the N10–C11 imine functionalities
had been converted to a lactam (Figure 6C). Interestingly, an
example of this type of dimer (n= 1) was still cytotoxic, but
with a level of activity approximately 40-fold lower than the
bis-imine parent molecule (i.e., Figure 6B; n= 1) suggesting
that, although the molecule could no longer cross-link DNA,
some form of DNA interaction (presumably mono-alkyla-
tion) was still occurring. A series of C2/C2’-linked dimers
have also been synthesized by Lown and co-workers (Fig-
ure 6D).[11b] Cytotoxicity studies indicated that one member
of the series (where n= 3) had an average LC50 of approx-
imately 50 mm across 60 tumor cell lines. Molecular dynamics
studies have since confirmed that the 3-dimensional shape of
both C8/C2’- and C2/C2’-linked PBD dimers is not conducive
to a good fit within the DNA minor groove.[62]
4. SJG-136: The First PBD Dimer to Undergo
Clinical Evaluation
As SJG-136 is the best known and most characterized
PBD dimer, the only example to reach clinical trials as
a single agent, and is similar in structure to those currently
being used as ADC
payloads, its biophys-
ical and biological
properties, sequence-
selectivity, and pre-
clinical and clinical
evaluation are de-
scribed below.
4.1. Biophysical and
Biological
Properties of SJG-
136
The DNA binding
affinity of SJG-136
was initially investi-
gated in DNA ther-
Figure 5. Examples of the main types of adducts that can form
between SJG-136 (6a) and DNA (i.e., interstrand and intrastrand
cross-links, and mono-adducts) (X=any base).
Figure 6. Examples of C8/C2’- and C2/C2’-linked PBD dimers synthesized by the Thurston,[11a] Kamal[61] and Lown[11b]
groups. Dimer 6C differs from the others in possessing only one electrophilic N10–C11 imine moiety, and so cannot
cross-link DNA.
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mal denaturation studies using calf thymus DNA.[10] The DTm
values obtained (Table 1) demonstrated an increase in DNA
melting temperature for each ratio after various incubation
times at 37 8C. A gradual increase in helix melting temper-
ature to 33.6 8C and 34.4 8C after 18 h and 72 h incubation,
respectively, for a 1:5 ratio (SJG-136/DNA) was obtained with
a significant stabilization effect already evident at t= 0,
suggesting a strong kinetic component to the interaction. It is
noteworthy that the DTm values obtained were significantly
higher than for the PBD monomers tomaymycin and
sibiromycin under identical conditions, with sibiromycin
providing the highest DTm value at 18 hours for all of the
known naturally occuring PBD monomers.[10,21] The extent of
interstrand cross-link formation produced by SJG-136 was
also investigated using a gel electrophoresis assay developed
by Hartley and co-workers.[10,63] It was evaluated at concen-
trations between 0.001 to 10 mm with pBR322 DNA (0.2 nm),
producing highly efficient DNA cross-linking (Figure 7a).
After 2 h incubation of DNA with SJG-136, cross-links were
visible starting from a concentration as low as 0.01 mm, with
single-stranded DNA disappearing completely at 0.3 mm. The
degree of cross-linking was quantitated using laser densitom-
etry as shown in Figure 7b. Overall, these results demon-
strated the high potency of SJG-136 as a DNA interstrand
cross-linking agent.
Molecular modeling studies of cross-link formation were
carried out to support the observations made in the thermal
denaturation and DNA cross-linking studies.[10] The results
suggested that either no or insignificant disruption to DNA
secondary structure occurred upon adduct formation and
cross-linking, and that no induced distortion of base pairs was
evident within the helical structure.[10] Overall, energy-mini-
mized models demonstrated excellent accommodation of
SJG-136 within the minor groove, with no significant part of
the molecule exposed beyond the periphery of the duplex.
DNA repair is usually initiated after repair enzymes recog-
nize distortion or helical perturbations of the DNA helix
(which usually occurs after interaction with the majority of
DNA alkyating agents[64]), and so the excellent accommoda-
tion of SJG-136 in the minor groove may explain the observed
resistance of its adducts to DNA repair. These computational
studies allowed models to be created for the interaction of
SJG-136 with DNA (Figure 8) consistent with the high DTm
values observed (Table 1).
Initial evaluation of the in vitro cytotoxicity of SJG-136
was carried out in the human ovarian carcinoma cell lines
SKOV-3, A2780 and CH1, together with their cisplatin-
resistant counterparts, A2780cisR and CH1cisR, using 96 hour
continuous exposure in the sulforhodamine B (SRB) growth
delay assay.[65] The IC50 (half maximal inhibitory concentra-
tion) values obtained demonstrated a significant cytotoxic
effect, with one of the lowest IC50 values obtained at the time
for any synthetic PBD monomer or dimer, and significantly
lower (i.e., 1500-fold lower in CH1) than for cisplatin.
Furthermore, in the A2780/A2780cisR pair of cell lines,
Table 1: Thermal denaturation data for the interaction of SJG-136 with
calf thymus DNA after incubation at different ratios for 0, 4 and 18 hours
at 37 8C.[10, 21] [a,b]
Compound [PBD]:[DNA]
molar ratio
Induced DTm (8C) after
incubation at 37 8C for:
0 h 4 h 18 h
SJG-136 1:100 7.1 8.0 9.1
SJG-136 1:50 11.3 12.3 15.0
SJG-136 1:5 25.7 31.9 33.6
Tomaymycin 1:5 0.97 2.38 2.56
Sibiromycin 1:5 – – 16.3
[a] Values for tomaymycin and sibiromycin under identical conditions are
provided for comparison. [b] The induced DTm for a 1:5 [SJG-136]:[DNA]
molar ratio after 72 hours incubation at 37 8C was 34.48C.
Figure 7. A) Autoradiograph of a denaturing agarose gel showing DNA
interstrand cross-linking of linear 32P-end-labeled pBR322 DNA (at
0.2 nm) by SJG-136 following a 2 h incubation at 37 8C. The lanes are:
C, double-stranded DNA control; 0, single-stranded DNA control; and
0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1.0, 3.0, 10.0 mm SJG-136. DS and SS
are double- and single-stranded DNA, respectively. B) Quantification of
the gel in (A) to show the concentration dependence of DNA cross-
linking for SJG-136 in linear 32P-end-labeled pBR322 DNA.[10] Reprinted
with permission from S. J. Gregson, et al. (2001), J. Med. Chem. 44,
737–748. Copyright 2001 American Chemical Society.
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SJG-136 produced extremely low IC50 values of approxi-
mately 0.00002 mm with little cross-resistance (i.e., resistance
factor= 1.1). Similar observations were made in the intrinsi-
cally cisplatin-resistant cell line SKOV-3, in which SJG-136
had an IC50 value of 0.0091 mm compared to 10.5 mm for
cisplatin.
The effect of SJG-136 on DNA processing was initially
studied in parallel DNA footprinting and in vitro transcrip-
tion stop (T-Stop) assays.[66] The sequence selectivity of SJG-
136 toward isolated DNAwas initially studied using a 262-bp
duplex DNA sequence from the MS2 plasmid which con-
tained the predicted interstrand cross-linking site for SJG-136
(i.e., 5’-Pu-GATC-Py-3’) in addition to less-favored sites (i.e.,
5’-GXXC-3’; X= any base)[10] (Figure 9A). The sequence
included two preferred binding sites at the two positions 5’-
48GGATCC53-3’ and 5’-208GGATCC213-3’, together with 17
other less-favored potential binding sites containing the
sequence 5’-GXXC-3’. As anticipated, the molecule was
observed to bind with high affinity to the 5’-48GGATCC53-3’
and 5’-208GGATCC213-3’ sites, but also bound to a number of
other 5’-GXXC-3’ sites (where XX was TA, GC, CT, TT, GG
or GT) with lower affinity. This result was surprising at the
time of publication, given that a guanine residue should not
be well-tolerated between two cross-linked guanines due to
the relatively bulky nature of guanine C2-exocyclic amino
groups which point into the minor groove. However, based on
more recent studies demonstrating that SJG-136 can form
mono-adducts and intrastrand cross-links in addition to
interstrand cross-links,[14] this observation can now be
explained by the formation of these other adduct types.
To investigate whether the in vitro and in vivo biological
activity[57] of SJG-136 could be due to sequence-selective
inhibition of transcription, a T-Stop assay was carried out on
a 282-bp DNA sequence to investigate its effect on T7 RNA
polymerase and transcription termination (Figure 9B).[22,66]
Significant transcriptional stop sites (T-stops) were observed
which appeared to be mainly associated with 5’-GXXC-3’
sequences. Although this assay could not distinguish between
mono-alkylated and cross-linked adducts, at the time of
publication the T-stops were assumed to be mainly associated
with interstrand cross-links.[22] In accord with the DNA
footprinting experiments (Figure 9A), one of the most
favored cross-linking sites (i.e., 5’-48GGATCC53-3’) gave the
strongest T-stop. The kinetic behavior of SJG-136 was also
studied by time-dependent experiments which showed that
incubation with DNA for 15 minutes was sufficient to inhibit
transcription with negligible changes after this up to 1 hour
incubation. Intriguingly, once transcription had been initi-
ated, addition of SJG-136 had negligible effect, suggesting
that adducts needed to be fully formed before they could
block transcription (Figure 9B). Additional temperature-
dependent experiments suggested that the activation energy
for covalent SJG-136/DNA interaction must be very low at 5’-
Pu-GATC-Py-3’ sites, since footprints were clearly detectable
at these sites on the gels at 4 8C. In contrast, the activation
energy for the less preferred 5’-39GGTACC44-3’ site must be
higher, as the strongest footprint was only observed at 37 8C.
Further evidence for the effect of SJG-136 on DNA process-
ing was derived from a restriction endonuclease inhibition
assay (the RED50 assay) which showed that it can inhibit
cleavage of the pGL3-C plasmid at the BglII sequence 5’-
AGATCT-3’ (a preferred SJG-136 cross-linking site) at low
concentrations.
Next, cross-link formation in tumor cell lines was studied
using the single cell electrophoresis (Comet) assay to
correlate the extent of DNA cross-linking with cytotoxicity.[67]
SJG-136 was initially evaluated in eight different cell lines
using the MTT growth inhibition assay, and an average GI50
(concentration for 50% maximal inhibition of cell prolifer-
ation) of 212 pm was determined (range: 2.1 pm in ovarian
A2780 to 2.3 nm in colon HCT-15).[67] The Comet assay was
then used to detect DNA interstrand cross-links in some of
these cell lines following a one hour exposure to SJG-136 at
0.1 nm to 10 mm. The Comet assay involves exposure of cells to
X-rays which cause the nuclear DNA to fragment and
electrophorese with a long (i.e., Comet-like) tail. However,
if the cells have been pre-treated with a DNA cross-linking
agent such as SJG-136, the DNA fragments are held together
and electrophorese as a more-singular entity. Using this
methodology, cross-linking was detected at very low SJG-136
concentrations (e.g., 0.5 nm in the K562 cell line), with cross-
links persisting over a 48 hours period.
Figure 8. A) Schematic diagram of the PBD dimer SJG-136 forming an
interstrand cross-link with the DNA sequence 5’-AGATCT-3’. Its
sequence-selectivity is due in part to a) covalent bonds formed
between the C11/C11’-positions of the PBD units and the exocyclic C2-
amino groups of guanines on both strands, and b) hydrogen bonds
(shown as a) formed between the N10-H/N10’-H protons of the
PBD units and the ring nitrogen N3 acceptors of the 3’-adenines
adjacent to the covalently modified guanines.[37a] B) Molecular model
of SJG-136 forming an interstrand cross-link within the sequence 5’-
TATAGATC(G)TATA-3’ (covalently modified guanines underlined, and
the guanine on the opposing strand in brackets) between the guanines
on each strand (both magenta).
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Similar studies were carried out using the g-H2AX
assay[68] which is more sensitive than the Comet assay[69] in
its ability to detect DNA damage caused by DNA cross-
linking agents. g-H2AX is a phosphorylated histone protein
which is rapidly recruited in the form of “foci” to sites of
replication fork collapse or DNA double-strand breaks
induced by cross-linking agents.[70] This provides a signal to
recruit DNA repair and cell cycle checkpoint enzymes to
initiate repair. These foci can be visualized using immunos-
taining techniques, and the number of foci present is propor-
tional to the extent of DNA damage. Therefore, the g-H2AX
assay has become an important and useful biomarker assay
for measuring the DNA damage caused by DNA cross-linking
agents.[71] An initial study was carried out to establish whether
the assay could correlate the appearance of g-H2AX foci in
HCT-116 cells with the rate of interstrand cross-link forma-
tion by SJG-136.[72] The cells were exposed to either 50 nm
SJG-136 for 1 hour, or 1 nm for 24 hours, and significant foci
formation was detected under both conditions at 4 hours or
8 hours post treatment, respectively (Figure 10). Despite
these exposure time differences, the levels of g-H2AX foci
formed in both cases were comparable after 24 hours. Parallel
experiments using the Comet assay showed that interstrand
cross-links were formed earlier with the higher dose (i.e.,
maximum reached after 1 hour for the 1 hour/50 nm treat-
ment), but maximum cross-link formation was reached only
after 24 hours for the lower 1 nm treatment. These results
were consistent with the need for DNA adducts to form prior
to the appearance of g-H2AX foci.
Studies were also carried out to investigate whether the
cytotoxicity of SJG-136 in colon cancer cell lines is dependent
on the expression of P-glycoprotein (P-gp),[73] as over-
expression is responsible for the resistance of many tumor
cell types to DNA-interactive agents.[74] SJG-136 was initially
evaluated in a range of colon and ovarian tumor cell types
known to over-express P-gp[73] The results revealed a decrease
Figure 9. A) Footprinting gels showing the interaction of SJG-136 with the MS2 DNA sequence (10 nm) at concentrations of 0.1, 1, 3, 10, 30, and
100 mm (left panel= top strand [MS2-F]; right panel=bottom strand [MS2-R]). The labels to the right of each gel correspond to the potential
binding sites.[66] B) T-Stop assay based on the same DNA sequence, showing the effect of incubation time on the ability of SJG-136 (at 1.0 mm) to
inhibit transcription. The right-hand side of the panel shows that most stop sites were already visible after only 15 min incubation of SJG-136 and
the DNA together prior to addition of transcription buffer, and that there was little significant change up to 60 min incubation. The left-hand side
of the panel shows that, once transcription had started (t=0), there was little effect upon adding SJG-136 at either 30 or 60 min time points
(labeled as 30 and 60 min, respectively). The marker numbers on the right of Panel (B) represent DNA length in base-pairs.[66]
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in IC50 of up to 10-fold after 24 hours treatment with SJG-136
in the presence of verapamil, suggesting that P-gp could be
causing SJG-136 efflux in these cells. Similar studies were
undertaken in the adriamycin-resistant A2780AD ovarian cell
line known to over-express P-gp due to up-regulation of the
mdr-1 gene, and in its non-resistant parent cell line A2780. As
anticipated, after 24 hours incubation, the parent cell line was
more sensitive to SJG-136 (i.e., IC50= 0.27 pm) compared to
the resistant A2780AD line (i.e., IC50= 13 nm). Pre-treatment
with verapamil resulted in a greater increase in cytotoxicity in
the doxorubicin-resistant cell line (i.e., A2780, IC50= 0.13
pM; A2780AD, IC50= 0.7 nm), further supporting the possibil-
ity that SJG-136 is a substrate for P-gp. In vivo human tumor
xenograft mouse models based on these cell lines were also
investigated. In A2780 xenograft models at doses of
300 mgkg1 as a single IV injection or 120 mgkg1 daily for
5 days (i.v), a significant decrease in tumor volume was
observed along with growth delay, whereas no significant
response was observed in the adriamycin-resistant A2780AD
xenografts regardless of the dose or schedule.
Finally, the influence of SJG-136 on cell cycle was studied
in HCT-116 cells (colon carcinoma) at high concentration
(50 nm) for 1 hour and low concentration (1 nm) for 24 hours
using flow cytometry. After the shorter exposure to the higher
concentration of SJG-136, a more prominent S-phase arrest
followed by transition to G0/G1 phase after 48 hours was
observed, consistent with rapid interstrand cross-link forma-
tion. In contrast, longer exposure to the lower concentration
of SJG-136 induced limited S-phase arrest and re-entry into
G0/G1 phase after 72 hours.
[72]
4.2. Sequence-Selectivity of SJG-136
The traditional methods used to evaluate the sequence-
selectivity and interstrand cross-linking ability of small
molecules are mostly based on gel electrophoresis methods
involving drug-treated radiolabeled duplex DNA (e.g., Fig-
ure 7A).[63] If the duplex DNA is cross-linked in an inter-
strand manner, then it runs as the double-stranded form on
the gel despite the denaturing conditions. The resulting band
on the gel is then quantitated by densitometry (e.g., Fig-
ure 7B). However, HPLC/MS methodology has also been
developed[75] that requires only small quantities of inexpen-
sive short non-radiolabeled oligonucleotides. More impor-
tantly, the adducts formed can be rapidly visualized (i.e., in
< 30 min), and so both kinetic and thermodynamic data can
be obtained, along with sequence selectivity information if
different oligonucleotides are used. Initial studies of SJG-136
using this methodology involved the self-complementary 12-
mer oligonucleotides containing Pu-GATC-Py (Seq-1), Pu-
GTAC-Py (Seq-2), Py-GATC-Pu (Seq-3) and Pu-IATC-Py
(Seq-4) sequences (I= Inosine) (Figure 11A). The results
clearly established the kinetic and thermodynamic preferen-
ces of SJG-136 for these sequences (Figures 11B and C), with
a rank order of Seq-1 > Seq-2 > Seq-3 > Seq-4).
Based on gel assays, until the late 2000s the biological
activity of SJG-136 was thought to be entirely due to Pu-
GATC-Py interstrand cross-links.[10,66,76] However, through
HPLC/MS studies reported since then, it has become clear
that SJG-136 is capable of forming longer interstrand cross-
links at Pu-GAATC-Py sequences, intrastrand cross-links at
standard-length Pu-GATG-Py and longer Pu-GAATG-Py
sequences, and mono-alkylated adducts at guanine residues
where cross-linking is not possible because of the distance
between potentially reacting guanines.[14] Similar studies have
shown that SJG-136 can also form interstrand and intrastrand
cross-links with shorter Pu-GAC-Py and Pu-GAG-Py sequen-
ces, respectively.[58a] In these experiments (Figure 12), inter-
strand cross-link formation at the usual Pu-GATC-Py[66]
sequence was initially confirmed using a 12-mer double-
stranded oligonucleotide containing this preferred sequence.
The possibility of intrastrand cross-link formation was then
investigated using a similar 12-mer DNA duplex mutated to
contain a 5’-AGATGT-3’ sequence. HPLC and MALDI-
TOF-MS analysis confirmed the formation of an intrastrand
adduct, although the rate of formation was much slower (i.e.,
incomplete after 24 hours) compared to the standard inter-
strand cross-link of similar length. In addition, mono-alky-
lated adducts were observed in this study, confirmed by their
HPLC retention times and MALDI-TOF-MS data. Previous
modeling studies[15] had suggested that insertion of an addi-
tional base pair between reactive guanines would prevent
Figure 10. The results of a g-H2AX Foci assay used to study the
adducts formed by SJG-136 in HCT-116 cells. The panels show the
concentration- and time-dependent phosphorylation of histone g-H2AX
in response to treatment with SJG-136. HCT-116 cells were exposed for
either 1 h at 50 nm or 24 h at 1 nm, fixed at 1, 4, 8 and 24 h after the
start of the time course, and then immunostained with an anti-
phospho-histone g-H2AX antibody.[72]
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cross-link formation due to loss of the preferred Pu-GATC-Py
motif. To investigate this, reaction with oligonucleotides
containing the extended Pu-GAATC-Py and Pu-GAATG-
Py sequences designed for interstrand and intrastrand cross-
link formation, respectively, was studied. Surprisingly, SJG-
136 was able to form cross-linked adducts with both
sequences, although rates of reaction were slower compared
to interstrand cross-link formation with the standard-length
Pu-GATC-Py. Finally, a direct competition experiment was
carried out between the interstrand Pu-GATC-Py and Pu-
GAATC-Py, and intrastrand Pu-GATG-Py and Pu-GAATG-
Py cross-link sequences. A rank order of reactivity of Pu-
GAATG-Py > Pu-GATC-Py  Pu-GATG-Py > Pu-
GAATC-Py was observed (Figure 12).
Molecular dynamics simulations were undertaken to gain
insight into these observations.[14] Energy-minimized models
indicated that the two electrophilic N10–C11 imine moieties
of SJG-136 are well-positioned to react covalently with the
two guanines in the Pu-GATC-Py (i.e., the favored inter-
strand cross-link) and Pu-GATG-Py (i.e., the shorter intra-
strand cross-link) sequences, with little distortion of the DNA
helix. However, for the extended Pu-GAATC-Py and Pu-
GAATG-Py sequences, the model predicted that bis-alkyla-
tion should only occur at the expense of some distortion of the
DNA helix at the points of covalent attachment, and with
SJG-136 adopting a slightly lower position in the DNA minor
groove in order to span the necessary distances between
reactive guanines. Interestingly, more recent HPLC/MS
studies[77] have established that SJG-136 can also bind to
a terminal guanine within duplex and hairpin oligonucleo-
tides, with the bulk of one of the PBD units positioned over
two rather than three base pairs. Previously, this was not
thought to be possible as, according to the literature,[60] PBDs
prefer to bind to a Pu-G-Pu triplet with a covalent bond
forming between the central guanine and the C11-position of
the PBD.
Other related HPLC studies have uncovered previously
unknown properties of PBD–DNA adducts. For example, it
has been demonstrated that a loss of minor-groove structure
through denaturation of the DNA helix results in dissociation
of the PBD/DNA adduct, although it can re-form upon
cooling.[78] Similar studies have shown that although PBD
molecules cannot form covalent adducts with single-stranded
DNA, they can stay covalently attached to DNA even if
a covalently-bonded duplex DNA adduct undergoes a com-
plete and permanent loss of minor-groove structure.[58b]
Together, these studies have demonstrated that a minor-
groove environment is required for covalent attachment,
although single-stranded adducts can exist if the duplex is
subsequently denatured. In addition, a dynamic equilibrium
has been observed between DNA hairpin and duplex forms of
covalent PBD/DNA adducts.[79]
Figure 12. Comparison of the reaction rates of SJG-136 with 12-mer
duplex oligonucleotides containing Pu-GATC-Py, Pu-GATG-Py, Pu-
GAATC-Py and Pu-GAATG-Py sequences. Reactions were monitored by
HPLC in separate experiments with a 4:1 molar ratio of SJG-136/DS-
DNA, and with adduct molecular weights and stoichiometries con-
firmed by MS.[14] The x-axis is time in hours (t/h).
Figure 11. A) Structures of the double-stranded (DS) oligonucleotides used to study interaction with SJG-136 in initial HPLC/MS studies.[75]
B) Graph of % cross-linking (% CL) versus time for duplexes Seq-1 to Seq-4 for a molar ratio of 4:1 (SJG-136/DS-DNA). C) Same data as in Panel
B but plotted against log time to provide rate data from the gradients (Units=% cross-linking, log h1). For Panels B and C, 0 h corresponds to
approximately 5 min after initial mixing of the duplex DNA and SJG-136. Seq-4 had all guanines replaced with inosines, and so was unreactive. All
data points are the means of triplicate measurements from independent experiments, with error bars showing  standard errors. Reproduced with
permission from: M. Narayanaswamy, et al., Anal. Biochem. 374, 173–181.[75]
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Overall, these HPLC and modeling studies have demon-
strated that SJG-136 can form a wider variety of covalent
DNA adducts than originally thought, which has led to a re-
evaluation of the previously proposed mechanism of action
involving only interstrand cross-linking at Pu-GATC-Py sites.
In particular, the discovery that PBDs including SJG-136 can
bind to terminal guanines[80] suggests that, in cells, they may
be able to bind to the ends of double-strand DNA breaks,
a previously unconsidered mechanism of action.
4.3. Preclinical Evaluation of SJG-136
In the late 1990s, SJG-136 was evaluated in the National
Cancer Institutes (NCIs) 60-cell line panel[81,82] in which it
showed promise in terms of potency and selectivity
(Figure 13), with an average LC50 (i.e., concentration killing
50% of cells) of 7.4 nm and a range of 0.14 to 320 nm. The
significant differences between the LC50, TGI (i.e., total
growth inhibition) and GI50 (i.e., concentration causing
inhibition of proliferation of 50% of cells) values across the
different cell lines suggested that it had selective cytotoxicity
toward certain panels of cell lines and individual cell lines. For
example, the leukaemia and melanoma cell panels were
particularly sensitive. Furthermore, the overall cytotoxicity
profile of SJG-136 was compared to the approximately 60000
compounds in the NCIs database using the COMPARE
molecular target analysis program.[82] This suggested an
activity pattern for SJG-136 similar to some known DNA-
interactive agents (e.g., melphalan, cyclophosphamide, chlor-
ambucil), although it did not match cluster patterns associated
with any specific chemotherapeutic agents, thus reflecting its
unique mechanism of action.
Based on these encouraging results from the NCIs 60-cell
line screen, SJG-136 was next evaluated in the Hollow Fibre
assay[76] to guide the selection of tumor cell types for
xenograft studies. This involved cultivation of selected
tumor cells in porous hollow fibre tubes which were
implanted into the intraperitoneal (i.p.) and subcutaneous
(s.c.) compartments of host immunocompromised mice.
These cells were then exposed to SJG-136 by systemic
administration (once daily for four days, i.p.) followed by
Figure 13. Averaged mean graphs (n=3) for the evaluation of SJG-136 in the NCI’s “In Vitro 60 Cell Line Screen”, showing graphic and tabular
listings of GI50, TGI and LC50 values (log units) for each cell line. The response of each cell line relative to the mean of all cell line responses is
depicted by a horizontal bar extending either to the right (more sensitive) or left (less sensitive) of the mean (vertical line) for each index of
activity. Reproduced with permission from: J. A. Hartley, et al., Cancer Res. 2004, 64, 6693–6699.[76]
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retrieval of the hollow fibres after 4 days, and quantitation of
the viability of the cells inside using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazol) assay.[83] In the
NCIs standard Hollow Fibre Assay,[76,83] SJG-136 was eval-
uated against 12 different tumor cell lines, and achieved
> 50% growth inhibition in 83% of the cell lines in the i.p.
cavity, and 29% in the s.c. location. Overall, it produced cell
kill in 5 of the 12 cell lines used in the study (i.e., NCI-H522
[lung adenocarcinoma], LOX IMVI and UACC-62 [mela-
noma], MDA-MB-435 [breast carcinoma] and OVCAR-3
[ovarian adenocarcinoma]). During the course of the experi-
ments, the average body weight loss in mice treated systemi-
cally with SJG-136 was  9% with no drug-related deaths,
indicating that the agent was well tolerated.
Based on these results, the NCI evaluated the in vivo
efficacy of SJG-136 in a number of human tumor xenograft
mouse and rat models[57,65b] using tumor cell lines selected
from the 60 cell line screen and Hollow Fibre Assay
data.[76,81,83] SF-295 and LOX IMVI were selected for assess-
ment of maximum tolerated dose (MTD) and minimum
effective dose (MED) in the mouse model, which were
established as 120 mgkg1day1 and 16 mgkg1day1, respec-
tively. Additionally, HL-60 TB and NCI-H522 were selected
for evaluation of different dosing schedules. SJG-136 was
well-tolerated and highly efficacious in both models, with HL-
60 TB found to be the most sensitive tumor type, and with
a once daily for five days schedule providing the best
antitumor activity in both models. In addition, a single
intravenous (i.v.) bolus regimen was compared with multiple
daily i.v. dosing in the SF-295 and LOX IMVI models.
Interestingly, an immediate tumor mass reduction was
observed in both models after the single dose administration
(MTD for single bolus= 400 mgkg1day1), although tumor
re-growth occurred within the next four days. In contrast,
daily administration of SJG-136 appeared to be more
effective in maintaining growth suppression and/or tumor
regression. Continuous infusion of SJG-136 was also explored
in the SF-295 and LOX IMVI xenograft mouse models but
did not provide any greater efficacy compared to bolus
administration.
Overall, significant tumor growth delays were observed in
seven of the eight models studied after i.v. administration at
doses between 25–100 mgkg1, with dose dependency after
multiple daily i.v. administration, and with greater efficacy
following drug accumulation (i.e., daily for five days more
efficacious than every fourth day for three treatments, or
a single dose), and with multilog cell kill in four of the eight
models. SJG-136 failed to show activity in only one model
(based on LOX IMVI) which was thought to be due to the
mode of administration (i.e., s.c. rather than i.v.),[57] although
the reasons for this are not fully understood.
Efficacy of SJG-136 in a xenograft model based on the
cisplatin-sensitive human ovarian cancer parental cell line
CH1 and its cisplatin-resistant equivalent CH1cisR was also
studied.[76] It was found to have significant antitumor activity
in the CH1 model, providing tumor growth delays at a dose of
0.2 mgkg1 administered i.v. on days 0, 4 and 8, comparable to
4 mgkg1 of cisplatin using the same schedule. It also
produced significant growth delay in the CH1cisR model at
0.2 mgkg1 on the same schedule whereas cisplatin was
inactive at 4 mgkg1,[76] supporting the hypothesis that SJG-
136 produces non-distortive DNA adducts that do not trigger
DNA repair.
In order to evaluate the pharmacokinetics of SJG-136 in
the animal models, and to develop methodology that could be
used in clinical trials, a reversed-phase LC/MS assay was
initially developed.[84] Using this assay, SJG-136 was detected
in plasma in the mouse models up to 4 hours after a single
intraperitoneal administration of 0.2 mgkg1, with a peak
plasma concentration (Cmax) of 336 nm after 30 minutes,
a half-life (t1/2) of 0.98 h, and a total clearance of
17.72 mLmin1kg1. Furthermore, it was shown to be stable
in mouse blood and plasma in vitro over a 6 hour period at
37 8C with no significant loss due to degradation, and the
plasma protein binding capacity was found to be 65 11%
and 76 5% for initial concentrations of 100 nm and 1000 nm,
respectively. Comparable pharmacokinetic studies were car-
ried out in a rat model following single-dose (15 and
50 mgkg1) and multiple-dose (25 mgkg1day1 for 5 days)
administrations using a similar LC/MS/MS method,[20] and no
plasma accumulation was observed after administration of
25 mgkg1day1 for 5 days. An alternative HPLC-based assay
was developed to quantify the reactive imine form of SJG-136
which proved to be accurate, reproducible and linear.[85] The
metabolism of SJG-136 was also evaluated in a rat liver
microsome assay, and it was found to be metabolized by
CYP3A isoforms[20] resulting in oxidative cleavage of the C8/
C8’-propyl linker and the release of two PBDmonomer units.
To study the pharmacodynamic (PD) endpoint of the
mechanism of action of SJG-136 in the in vivo xenograft
models, the Comet assay was used to evaluate tumor biopsies
taken from a subcutaneous-growing LS174T human colon
cancer in MF1 nude mice.[86] SJG-136 caused a significant
growth delay in this tumormodel when delivered i.v. at 0.30 or
0.45 mgkg1, and so tumor samples were removed at 1, 3 and
24 hours, and then subjected to Comet analysis. A small but
significant level of DNA cross-linking was observed for the
0.3 mgkg1 dose after 1 hour which remained constant over
24 hours. The extent of cross-linking increased with the higher
dose of 0.45 mgkg1, and this also remained constant over
24 hours.[86] Finally, an ex vivo bone marrow colony formation
(CFU-GM) assay was used to assess the toxicity of SJG-136
toward the hematopoietic system.[76,87] The results demon-
strated that the concentrations of SJG-136 required to
achieve cytostatic and/or cytocidal effects in HL-60 TB and
Molt-4 human leukaemia tumor cells in culture or in a soft
agar colony formation assay (i.e., 0.14 to 70.8 pmolL1) were
significantly lower than the concentrations required for
similar effects in the ex vivo bone marrow assay[76] (i.e., 16.2
to 536 pmolL1), suggesting a selective cytotoxicity toward
the tumor cells and a potential therapeutic window.
In summary, SJG-136 showed significant antitumor activ-
ity in most of the in vivo models examined based on a wide
variety of tumor types. Activity was observed after a single
bolus administration, although it gave the best efficacy after
multiple administrations over a five-day period.[57] These
encouraging results, coupled with data demonstrating a linear
pharmacokinetic profile and differential cytotoxicity between
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leukaemia and bone marrow cells, led to the decision to
evaluate SJG-136 in Phase I clinical trials.
4.4. Clinical Evaluation of SJG-136
The first clinical evaluation of SJG-136 as a single agent in
a Phase I setting was carried out at University College
London and Edinburgh University (UK) between 2004 and
2006 in patients with advanced and/or metastatic solid
tumors.[18b] Based on data from pre-clinical toxicology studies
in mice, rats and dogs,[57,88] it was initially administered as
a 10 minute i.v. infusion every 21 days at a starting dose of
15 mgm2 (i.e., 1/16 of the total dose given to dogs) which was
doubled until drug-related adverse events were observed.
This 21-day schedule was adopted due to the myelosuppres-
sion often associated with DNA-interactive agents after bolus
administration. A MTD of 45 mgm2 was established for this
schedule. Pharmacokinetic (PK) analysis[18b,84] of urine and
blood samples showed a linear relationship between AUC0–8h
or Cmax and dose over the dose range studied (i.e., 15–
240 mgm2), and results from the Comet[69] and g-H2AX
foci[71] assays on both peripheral blood lymphocytes and
tumor tissue confirmed that SJG-136 induced DNA cross-
links with a maximum induction period of 24 hours post-dose.
Out of twelve evaluable patients, stable disease (SD) was
observed in ten patients, but no partial (PRs) or complete
responses (CRs) occurred. Although bone marrow toxicity
had been anticipated, surprisingly the major dose-limiting
toxicities (DLTs) observed were reversible liver toxicity (i.e.,
transaminitis), fatigue and, in some patients, a delayed lower-
limb oedema which could usually be resolved with diuretics.
At this time, the oedema was not classified as vascular leak
syndrome, as only the lower limbs were involved with most
affected patients presenting only with swollen ankles,
although in a small number of patients the entire legs were
involved.
A second Phase I clinical trial with a different dosing
schedule was carried out between 2004 and 2007 at the
Memorial Sloan-Kettering Cancer Center and the University
of Kentucky (USA) in patients with refractory solid tumors
using a starting dose of 10 mgm2 per day administered as
a bolus infusion over 20 minutes on days 1, 8 and 15 of a 28-
day cycle.[18a] DLTs became evident at a dose level of
60 mgm2 per day as fatigue (42%), thrombocytopenia
(14%) and delayed transaminitis (33%), all at the Grade 3
level. Immediate transaminitis, oedema and hypoalbumine-
mia were also experienced by some patients. On this basis, the
MTD was determined to be 40 mgm2 per day on this
schedule, and linear pharmacokinetics were demonstrated in
the evaluated dose range of 10–60 mgm2 per day, with dose-
proportional increases of SJG-136 following systemic expo-
sure.[89] Although no PRs or CRs were observed, of the 13
patients in the trial, one had stable disease (SD) lasting for 8
cycles.
A third Phase I clinical trial was carried out between 2005
and 2008 at the Vanderbilt University Medical Center (USA)
in patients with advanced solid tumors.[90] Based on the
outcomes from one of the previous clinical trials,[18b] this study
evaluated two different dose schedules. In Schedule A,
patients were given doses of 6, 12, 24, or 48 mgm2 per day
for 5 consecutive days of a 21 day cycle with the aim of
studying DLTs and PK after multiple dosing. In this case, the
major DLTs observed included delayed oedema, reversible
liver toxicity (i.e., elevations in liver transaminases and
alkaline phosphatase), dyspnoea, fatigue and hypoalbumine-
mia. Again, no myelosuppression was experienced by any of
the patients. Based on these DLTs, patients in Schedule B
were given doses of 20, 25, 30 or 35 mgm2 per day for 3
consecutive days of a 21 day cycle, a shorter and more
conservative schedule. It also included dexamethasone pre-
treatment and early diuretic (i.e., spironolactone) adminis-
tration if oedema occurred. For this schedule, a MTD of
30 mgm2 was determined, with DLTs similar to those
previously documented. However, in contrast to the DLTs
observed in Schedule A, they were manageable with the use
of steroids and diuretics. PK analysis suggested a dose-
dependent increase in systemic exposure to SJG-136 in Cycle
1 in both Schedules. Comet assay analysis of peripheral blood
mononuclear cells (PBMCs) taken from patients in Schedule
B showed detectable DNA interstrand cross-link formation
prior to dose 3 of Cycle 1, which was in broad agreement with
the systemic exposure calculated from the AUC and Cmax
values determined in the PK studies. Further analysis
indicated persistent DNA cross-link formation still detectable
prior to the first dose of Cycle 2 for Schedule B. These data
confirmed the persistence of cross-links formed between SJG-
136 and DNA, and the ability of the adducts to avoid
recognition and repair by DNA repair enzymes.[10,76] In this
trial, of two patients with ovarian carcinoma, one experienced
a confirmed PR, and the other an unconfirmed PR. In
addition, one patient with small cell lung carcinoma, and one
with bladder carcinoma, achieved SDs lasting more than
12 weeks.
A final multicenter Phase I clinical evaluation of SJG-136
was carried out at the Sloane Kettering, M.D. Anderson and
Ohio State University clinical centers in the US, but the
results of these trials have not yet been published.
On the basis of these encouraging Phase I results, SJG-136
progressed to a multicenter Phase II clinical evaluation in
patients with epithelial ovarian cancer not responding to
cisplatin or carboplatin. This study, carried out by the NCI
between 2010 and 2013, enrolled nineteen patients on
a schedule of 30 mgm2day1 for 3 consecutive days of a 21
day cycle. For each patient, in addition to PK analysis, the
extent of DNA adduct formation was determined in PBMCs
and tumor biopsies using the Comet and g-H2AX assays.
However, patient recruitment to this trial was poor, and no
clinical results have been reported to date.
A second Phase II clinical evaluation of SJG-136 in
patients with advanced chronic lymphocytic leukaemia (CLL)
and acute myeloid leukaemia (AML) was started by the NCI
in 2014 and closed the following year. In this trial, patients
received SJG-136 at dose levels of 15 mgm2day1 (Cohort I)
or 30 mgm2day1 (Cohort II) on days 1, 2 and 3 every 21 days
for six cycles. In addition to establishing the MTD and
pharmacokinetic parameters, the aim was to obtain data from
bone marrow aspirates, pulse oximetry and electrocardiogram
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studies, although no clinical results have been reported to
date.
In summary, the main DLTs observed in the Phase I and
Phase II clinical trials were surprising in that bone marrow
suppression, neutropenia, GI disturbances and alopecia,
frequently observed for DNA-interactive agents (and cross-
linking agents in particular), were absent. Instead, the most
frequently observed side effects of lower limb oedema,
fatigue and transaminitis were all reversible, and could be
limited by pre-treatment of patients with the steroid dex-
amethasone. Similarly, the oedema, if problematic, could be
treated with a self-administered diuretic (i.e., spironolac-
tone). It is noteworthy that, overall, clinical signals of stable
disease and partial responses were observed.
5. PBD-Based ADCs in Clinical Development
During the last 30 years the use of monoclonal antibodies
in cancer therapy has gained increasing importance.[91] This
tumor-selective approach is based on the specific interaction
of antibodies with antigenic biomarkers (e.g., proteins,
glycoproteins or carbohydrates) on the surface of tumor
cells, or intracellular signalling proteins, essential for their
proliferation. One therapeutic approach is based on the use of
antibodies alone to bind to these tumor antigens which exert
an antitumor effect by attracting T-cells to the area (i.e., the
antibody-dependent cell-mediated cytotoxicity or “ADCC”
mechanism).[92] For example, the CD20-targeting antibody
Rituximab (Rituxan, Mabthera) is an example of this
approach, and is used as a single agent for the treatment of
non-Hodgkins lymphoma. However, an alternative approach
is to attach a cytotoxic chemical payload to the antibody
through a suitable linker to produce an antibody–drug
conjugate (ADC) (Figure 14).[91,93] The chemical payload is
chosen to be a highly cytotoxic small-molecule, protein or
glycoprotein that can be released at the tumor site through
cleavage of the linker, thus killing tumor cells while producing
minimal systemic toxicity. The first example of an approved
ADC, gemtuzumab ozogamicin (Mylotarg), was launched by
Wyeth (subsequently Pfizer) in 2000 for the treatment of
acute myeloid leukaemia,[94] although it has since been
withdrawn.[95] Currently two ADCs are approved for cancer
therapy, with over 55 others presently in early and late stage
clinical development.[91] Brentuximab vedotin (Adcetris),
developed by Seattle Genetics Inc in collaboration with
Takeda Oncology, targets the CD30 antigen, carries an
auristatin payload and is used in patients with anaplastic
large cell lymphoma (ALCL) and Hodgkins lymphoma. In
the latter disease it provides an overall response rate of 75%,
with approximately 35% and 40% complete and partial
responses, respectively. Similar results are obtained in ALCL,
with an overall 86% response rate, and 53% and 33%
complete and partial responses, respectively.[96] The second
ADC currently approved is ado-trastuzumab emtansine
(Kadcyla), developed by Genentech Inc, a subsidiary of
Roche. This ADC, which targets the HER2 receptor and
carries a maytansinoid payload, is used to treat metastatic
breast cancer.[97] In the clinic it has provided an overall
survival (OS) time of 30.9 months compared to 25.1 months
for treatment with a combination of lapatinib and capecita-
bine.
Since the approval of gemtuzumab ozogamicin (Mylo-
targ) in 2000, there has been a constant search for new
highly-cytotoxic molecules suitable for use as chemical pay-
loads for ADCs. The quest for novel payload molecules is
driven by a number of factors including the need to enhance
cytotoxic potency, avoid the development of resistance and
improve physicochemical properties, the availability and ease
of manufacture, and the novelty of the molecule and thus the
ability to protect by patenting. For example, the enediyne-
based payload of Mylotarg is particularly complex and
expensive to manufacture. Therefore, research in the 1990s
and 2000s led to payloads based on the auristatins and
maytansines which led to the commercially successful ADCs
brentuximab vedotin and ado-trastuzumab emantasine,
respectively, although the IP space around these two payloads
is now very restricted.
The PBD dimers were first studied as potential payloads
for ADCs in a research collaboration between Spirogen Ltd
and Seattle Genetics Inc in the mid to late 2000s. This led to
two PBD-based ADCs, SGN-CD33A[98] and SGN-CD70A[99]
(Figure 15), which are currently in Phase III and Phase I
clinical trials, respectively. This work also led to Seattle
Genetics sub-licencing its PBD dimer ADC technology to
Abbvie Inc. Both Seattle Genetics ADCs utilize a simple
valine–alanine (Val–Ala) dipeptide specifier unit between the
PBD dimer (SGD-1882) and the antibody, attached through
thiol residues (i.e., Cys239 groups) in the hinge region of the
antibody via a maleimidocaproyl (mc) linker. In the case of
SGN-CD33A, its antibody component is targeted to CD33
receptors on the surface of AML cells, and SGN-CD70A is
Figure 14. Schematic diagram of an ADC showing the general structure
of a typical antibody used for ADC construction. The antibody is
comprised of heavy (blue) and light (green) chains, and contains
antigen-binding sites at the N-terminus engineered to recognize
antigens associated with a tumor cell. The cytotoxic payloads are
connected via linkers to the antibody, with the example shown having
two payloads attached via cysteine residues in the hinge region. When
the ADC arrives at the tumor cell, the whole construct is typically
internalized and the linkers cleaved, usually by proteases, to release
the payload molecules which subsequently kill the cell.
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targeted to the CD70 antigen which is expressed on both renal
cell carcinoma and non-Hodgkin lymphoma cells but with
limited expression on normal cells. In both ADCs, the PBD
payload (SGD-1882) is an unsymmetrical C2/C2’-bis-aryl C2-
C3/C2’-C3’-endo-unsaturated C8/C8’-linked PBD dimer, con-
taining a C2’-para-methoxyphenyl substituent on the uncon-
nected end, and a para-aminophenyl C2-substituent on the
other end through which the Val–Ala specifier is attached.[100]
For SGN-CD33A, conjugation is achieved through a serine-
to-cysteine mutation at position 239 of the heavy chain of the
antibody (a solvent accessible location), resulting in selective
payload attachment with an average drug–antibody ratio
(DAR) of 1.9.
In pre-clinical studies SGN-CD33A demonstrated signifi-
cant in vitro and in vivo activity against a broad panel of
AML cell lines and in pre-clinical AML mouse models,[19]
respectively. For example, it had a mean IC50 of 22 ngmL
1
across 12 different AML cell lines, and was active in 15 out of
18 patient-derived primary AML samples with a mean IC50 of
8 ngmL1. Crucially, it had negligible activity in cell lines and
patient-derived samples having no or negligible CD33
expression, thus confirming the selectivity for this antigen.
Other experiments demonstrated CD33-dependent and dose-
dependent effects on the formation of CFU-GMs (colony
forming unit granulocytes/macrophages) in an ex vivo bone
marrow colony formation assay. Furthermore, in experiments
designed to confirm that the PBD dimer was released in
target cells with subsequent DNA interstrand cross-link
formation, AML cells were treated for up to 48 hours with
SGN-CD33A followed by evaluation with the g-H2AX foci
assay. A dose-dependent increase in g-H2AX foci formation
was observed from 16 to 24 hours after ADC exposure, and in
related Western blot experiments SGN-CD33Awas shown to
generate a dose-dependent down-regulation of p53, Chk1,
Chk2 and caspase-3 in HEL 92.1.7 AML cells. Finally, cell
cycle analysis in AML cell lines using flow-cytometry
revealed that G2/M arrest occurred after treatment with
SGN-CD33A, providing further evidence for successful
release of the PBD dimer from the ADC. SGN-CD33A was
also evaluated in several subcutaneous AML mouse xeno-
graft models based on HL-60, TF-1a and HEL 92.1.7 tumors
in which complete and persistent anti-leukaemic responses
were observed in all animals treated with a single dose of
100 mgkg1 or 1000 mgkg1,[98] although reduced cell prolifer-
ation was also observed at the lower dose of 30 mgkg1
compared to the non-treated control group. Furthermore, in
tumor models resistant to the CD33-targeting gemtuzumab
ozogamicin (e.g., HEL 92.1.7), SGN-CD33A had similar
potent anti-leukaemic activity with complete responses at
a single dose of 1000 mgkg1, and with 3 out of 7 mice still
tumor-free at the end of the study.
These encouraging pre-clinical results led to the initiation
of Phase I clinical trials in 2013 to evaluate the safety,
tolerability, PK and clinical activity of SGN-CD33A in acute
myelogenous, myeloid and promyelocytic leukaemia
patients.[101] The first trial involved 40 patients (48%
female) of average age 75 years, evaluating dose levels of
5 mgkg1 (n= 3), 10 mgkg1 (n= 3), 20 mgkg1 (n= 13),
40 mgkg1 (n= 18) and 60 mgkg1 (n= 3). A rapid and
marked decrease of bone marrow blasts was observed at the
dose levels of 40 and 60 mgkg1 in 19 out of 21 patients, and
complete disease remission occurred at the 5 (one patient), 10
(one patient) and 20 (two patients) mgkg1 dose levels.
Preliminary PK data showed an elevation in plasma concen-
tration of the agent with increasing dose levels followed by
rapid clearance, and a MTD of 40 mgkg1 was established.[101]
Two DLTs of Grade 3 pulmonary embolism (at 20 mgkg1)
and Grade 4 hypocellular marrow (at 40 mgkg1) were
observed after 28 days. Other less serious side effects were
encountered including Grade 3 febrile neutropenia, fatigue
and malaise, GI effects (e.g., diarrhoea, constipation), lung
toxicities (e.g., pleural effusion, cough and dyspnoea),
epistaxis, peripheral oedema and hypokalaemia. Overall, all
ADRs were manageable, and no treatment-related deaths
occurred. A Phase III combination trial was initiated by
Seattle Genetics in May 2016 to evaluate SGN-CD33A in
combination with a hypomethylating agent (i.e., either
azacitidine or decitabine) in older patients with newly
diagnosed AML.
A second PBD-based ADC developed by Seattle Genet-
ics, SGN-CD70A, uses an identical payload–specifier–linker
assembly to SGN-CD33A but is conjugated to the anti-CD70
antibody h1F6 (Figure 15).[102] As with SGN-CD33A, con-
jugation was achieved through the Cys-239 positions of the
heavy chains of the antibody to produce an average DAR of
1.9. In vitro evaluation of both the ADC and PBD dimer
payload alone gave nearly equivalent cytotoxicity in an
ACHN cell line, and in vivo studies in BALB/c mice
demonstrated that SGN-CD70A was well tolerated at
2.5 mgkg1 (single dose) with no weight loss. Human tumor
xenograft mouse models demonstrated pronounced antitu-
mor activity at doses as low as 0.1 mgkg1. For example, in the
ACHN model, a cure rate of 100% was observed based on
two weekly doses of 0.1 mgkg1. Furthermore, a non-Hodg-
kins lymphomamodel in SCIDmice was very sensitive to this
ADC, with 100% cures after two weekly 0.1 mgkg1 doses.
Figure 15. Structures of SGN-CD33A (Vadastuximab talirine; one of the first PBD-based ADCs to be developed), SGN-CD70A and SGN-CD123A,
all constructed from the same Val–Ala dipeptide specifier unit and PBD dimer payload (SGD-1882) linked to CD-33-, CD-70- and CD123-targeting
antibodies, respectively, via a maleimidocaproyl (mc) moiety. SGN-CD33A was developed through a research collaboration between Seattle
Genetics Inc and Spirogen Ltd, and is presently in Phase III clinical trials.
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Other experiments were carried out to confirm that the
biological activity of SGN-CD70A was consistent with the
known mechanism of action of PBD dimers,[103] such as
activation of DNA damage pathways and promotion of cell
death through G2 cell cycle arrest.[99] For example, an
immunofluorescence assay in which antibodies specific to
double-strand break repair proteins (i.e., Rad50 and Mre11)
were used to monitor DNA damage foci demonstrated that
foci were present after exposure to either SGN-CD70A or the
PBD dimer payload alone. Evidence for DNA strand break-
age was obtained through observation of increased levels of
phosphorylated Chk1 and Chk2 proteins (which both co-
ordinate DNA damage response) within 4 hours of treatment,
along with increased levels of pBRCA1.[103] The relevance of
the DNA damage pathway to mechanism of action was also
confirmed through experiments with small-molecule inhib-
itors of DNA damage-sensing kinases such as ATM, ATR and
members of the Chk family, which were all synergistic with
SGN-CD70A. Similarly, a Mps1 inhibitor capable of short-
ening mitosis and abrogating the mitotic checkpoint was also
synergistic.[99] Based on these promising pre-clinical results,
a multi-center, dose-escalation Phase I clinical trial was
initiated in 2014 to establish theMTD of SGN-CD70A, and to
evaluate its safety, PK and efficacy in patients with renal cell
carcinoma, Mantle-cell lymphoma and diffuse large B-cell
lymphoma.
Seattle Genetics has recently disclosed a third PBD-based
ADC, SGN-CD123A, consisting of a humanized anti-CD123
antibody targeted to CD123 (the alpha subunit of the IL-3
receptor expressed by the tumor cells of the majority of AML
patients) conjugated to the same dipeptide specifier and PBD
dimer payload (i.e., SGD-1882) through cysteines on each
heavy chain of the antibody (Figure 15) to provide a DAR of
approximately 2.[104] It was initially assessed in 12 AML cell
lines, four of which were MDR-positive, and was highly active
in 11 of these with a mean IC50 of 6 ngmL
1. It was also
assessed in 23 patient-derived primary AML samples with
varying cytogenic profiles, and was shown to be active in 20 of
these with a mean IC50 of 0.8 ngmL
1. Next, in vivo efficacy
was investigated in AML xenograft models based on both
MDR-negative andMDR-positive CD123-positive tumor cell
lines, and a single dose resulted in significant antitumor
activity in all models. For example, in the xenograft based on
the CD123-positive/MDR-negative cell line Molm-13,
a single dose of 10 mgkg1 resulted in complete cures and
significant survival compared to untreated or control ADC
groups.[104]
A fourth Seattle Genetics ADC (SGN-CD352A) target-
ing multiple myeloma has recently been disclosed.[105]
CD352A (SLAMF6) was found to be expressed in 87% of
multiple myeloma patient samples evaluated, thereby repre-
senting a viable ADC target. Studies have shown that
conjugation of an anti-CD352A antibody to an identical
payload complex to that used in SGN-CD33A (see Figure 15),
results in an ADC with potent in vitro cytotoxicity (i.e., EC50
of 2–7 pm) in both multiple myeloma (e.g., MM.1R) and non-
Hodgkins lymphoma (e.g., Ramos) cell-lines. Furthermore,
apoptotic cell death is activated in 48 hours, but the ADC
does not affect the viability of normal resting human
lymphocytes. SGN-CD352A has also been shown to have
potent in vivo activity in both multiple myeloma and non-
Hodgkins lymphoma xenograft models, where durable
responses were evident at single dose levels of between 30–
100 mgkg1.
Seattle Genetics has also reported studies on the
bystander effect associated with PBD-containing ADCs,[106]
demonstrating that an ADC comprised of a CD30+-targeted
antibody conjugated to a MC-Val-Ala-PBD dimer construct
(identical to that used in SGN-CD33A, SGN-CD70A and
SGN-CD123A) can produce substantial bystander killing
effects in neighbouring antigen CD30 cells in comparison to
a less membrane permeable CD30+-targeted ADC carrying
a MMAF payload. In these experiments, an admixed in vivo
tumor model based on both Karpas-35R (CD30 , and CD30-
VC-MMAE resistant) and Karpas-299 (CD30+) cells was
developed. It was shown that when the level of Karpas-299
CD30+ cells was reduced to 34% in the admixed tumor
model, treatment with the CD30+ PBD ADC caused tumor
regression while the CD30-vcMMAE ADC gave only growth
delay. These results suggest that PBD-based ADCs appear to
require the presence of fewer antigen-positive tumor cells to
mediate bystander killing in vivo compared to an MMAE-
based ADC. This may be due to the superior potency of PBD
dimers, and/or their ability to diffuse across cell membranes at
a greater rate than MMAE payloads. In more recent work,[132]
Ma and co-workers at Genentech have investigated the
degree of DNA–PBD dimer adduct formation in tumour cells
in mouse xenograft models. This involved collection of tumor
and organ tissues from mice treated with the ADC, followed
by DNA isolation and payload recovery. This was achieved
through the use of Nuclease P1 to cleave the DNA to the level
of individual adducts which could then be quantitated using
a LC-MS technique. The results suggested that adduct
formation in tumour cells was highly efficient, with 80% of
the ADC entering tumors leading to DNA-drug adducts after
96 hours. Furthermore, the number of adducts in tumor
tissues was found to be 70-fold greater than in healthy tissues
(i.e., lung and liver) at a similar time point. The results also
allowed the researchers to calculate that there were 41 PBD
dimer adducts per million base pairs in tumor cells, compared
to only 1 PBD dimer per million base pairs in lung and liver
cells (and less in other organs such as the kidney). Impor-
tantly, these findings mirror clinical data for PBD-containing
ADCs, and highlight the advantages of PBD payloads
including clean release, direct DNA targeting and DNA
adduct stability.[132]
Along with SGN-CD33A developed by Seattle Genetics,
the DLL3-targeted ADC SC16LD6.5 (also known as roval-
pituzumab tesirine, or Rova-T) developed through a collabo-
ration between Stemcentrx Inc (recently acquired by Abbvie)
and Spirogen Ltd was one of the first PBD dimer-based
ADCs to enter the clinic. DLL3 is an antigen found in the
Notch signalling pathway, and is prevalent in neuroendocrine
tumors. Rova-T consists of a PBD dimer conjugated to a SC16
antibody through a cathepsin-B cleavable Val–Ala specifier
coupled to a PEG8 linker (Figure 16). Attached to the hinge-
region thiols of the antibody through maleimide coupling, the
conjugate has a DAR of 2. The C8/C8’-coupled PBD dimer
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payload used in this ADC contains a central pentamethylene
linker and is C2-C3/C2’-C3’-endo-unsaturated with C2/C2’-
bis-methyl substitution. These modifications to the PBD
dimer were introduced in an effort to enhance isohelicity with
the minor groove, and to reduce hydrophobicity.[107] The
payload is joined to the specifier via a para-aminobenzyl
alcohol (PAB) self-immolative spacer unit attached to one of
the N10-atoms of the PBD through a carbamate linkage,
a strategy previously disclosed in the patent literature by
Genentech Inc and Spirogen Ltd.[108]
In pre-clinical studies[110] the naked antibody itself, SC16,
was not cytotoxic toward either DLL3-null HEK-293T or
DLL3-expressing HEK-293T.hDLL3 cell lines, whereas the
PBD dimer alone and the full ADC (Rova-T) both had
significant cytotoxicity toward HEK-293T.hDLL3 cells, with
EC50 values of 46.9 pm and 7.8 pm, respectively. In addition,
Rova-Twas shown to be more effective than standard agents
in these cell lines[109] but had no cytotoxicity in the stat-null
HEK-293 cell line. Similarly, in the small-cell lung cancer cell
line LU64, Rova-T had an EC50 of 8.3 pm, whereas the PBD
dimer alone only achieved cell kill at concentrations of 500 pm
or above, demonstrating a significant enhancement in cyto-
toxic activity through antibody conjugation. Successful
knockdown of DLL3 expression by this ADC was also
demonstrated in flow cytometry experiments based on
patient-derived LU37 large cell neuroendocrine carcinoma
(LCNEC) cells transduced with a lentivirus expressing
a DLL3-targeted short hairpin RNA. Follow-on in vivo
studies[110] involved mouse models implanted with patient-
derived small cell lung carcinoma (SCLC) or LCNEC cells
with tumors grown to 140–200 mm before treatment. After
three cycles of 1 mgkg1 of Rova-T administered intraper-
itoneally every four days (i.e., q4D 3), complete responses
were obtained with no recurring tumors up to 144 days post-
dosing. To demonstrate payload-dependent activity, similar
xenografts treated with doses of up to 30 mgkg1 of non-
conjugated antibody, or free PBD dimer corresponding to the
concentration of payload on the ADC, provided no significant
inhibition of tumor growth. Finally, in LU64 tumor-bearing
mice, treatment with Rova-T provided a complete response
after the tumors had rebounded from initial treatment with
a cisplatin/etoposide combination. Based on these encourag-
ing pre-clinical data, a Phase I/II trial was initiated to establish
its safety and tolerability at different dose levels in SCLC
patients.[109] Preliminary results, presented at an American
Society of Clinical Oncology (ASCO) Annual Meeting in
2016, showed that 11 of 60 (18%) evaluable patients dosed
with Rova-T experienced tumor shrinkage, and 41 (68%)
received associated clinical benefit. Interestingly, DLL3-
specific activity was observed in patients experiencing the
best responses (i.e., 39%; 10 of 26 patients) in the DLL3-
positive sub-set. In these patients, median overall survival rate
was 5.8 months, with 32% of patients alive after 12 months.
On the basis of these encouraging Phase I/II results, Rova-T
recently entered Phase III clinical trials in SCLC patients.
The same PBD dimer payload (i.e., a symmetrical C8/C8’-
coupled C2-C3/C2-C3’-unsaturated C2/C2’-dimethyl PBD
dimer) has been used by Allozyne Inc. to generate a Her2/
neu-targeted ADC with a DAR of 1.9 (4D5-PBD, Figure 17).
4D5-PBD is unique in that it was constructed using “click”
chemistry to enable site-specific conjugation of the PBD
dimer to the antibody through one of its N10-positions via
a Val–Ala specifier and self-immolative PAB spacer. This was
achieved through introduction of a non-natural amino acid
containing an azide moiety at defined places within the
antibody which could react under very mild conditions with
an alkyne group at the terminus of the linker-payload
assembly to form a stable heterocyclic triazole linkage
between the payload and antibody. The click reaction
involved a copper-catalyzed cycloaddition process to attach
the payload to both H274 positions of the antibody. During
the design phase of this ADC, four potential conjugation sites
were chosen based on analysis of the IgG1 crystal structure,
and were selected for favorable characteristics such as
a position distal to the antigen binding site and hinge regions,
a location in a solvent-exposed region and outwardly
orientated to optimize ADC synthesis. This click chemistry
approach was also used by the same researchers to produce an
ADC based on the monomethyl auristatin F payload.
4D5-PBD was shown to have sub-nanomolar potency
across a number of relevant cell-lines (e.g., EC50 of 0.061 nm
and 0.504 nm in SKBR3 and SKOV3, respectively), but was
Figure 16. Structure of SC16LD6.5 (also known as rovalpituzumab tesirine, or Rova-T), a DLL3-targeted PBD-containing ADC developed by
Stemcentrx Inc through a collaboration with Spirogen Ltd. The PBD dimer payload is connected to the antibody through one of its N10-positions
via a self-immolative para-aminobenzyl alcohol (PAB) spacer unit, a cathepsin-B-cleavable Val–Ala dipeptide specifier and a PEG8 linker.
Conventional maleimide conjugation was used to provide a DAR of 2. Rova-T has recently entered Phase III clinical trials for patients with small-
cell lung cancer (SCLC).[109]
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marginally less potent in the same cells than a directly
equivalent MMAF-containing ADC (4D5-AF). Other studies
showed that 4D5-PBD was less potent in some cell lines than
trastuzumab-PBD, however this could be partly explained by
a DAR of 3 for the trastuzumab-PBD conjugate, whereas
4D5-PBD has a lower DAR of 1.8. Follow-on in vivo studies
showed little difference in activity between 4D5-PBD and
trastuzumab-PBD, with both being similarly effective in
inducing sustained tumor regression in nude mice implanted
with BT474 tumors. Interestingly, the MMAF-containing
ADC 4D5-AF did not provide curative effects at the same
dose level in the same model.
Developed by ImmunoGen Inc., IMGN779 (Figure 18) is
another PBD-related ADC that has reached the clinic.[111]
This ADC, like SGN-CD33A, targets CD33 receptors on the
surface of AML cells, but contains an indolinobenzodiazepine
moiety (referred to as an “IGN” by the company) as the
cytotoxic payload. There are four unique features of this
cytotoxic payload that distinguish it from the PBD dimers.
First, the IGN structure DGN462 is based on two coupled
indolinobenzodiazepine structures comprising two PBD skel-
etons with each containing an addi-
tional D-ring attached to the C-ring.
The D-ring is thought to act as an
improved bioisosteric equivalent to
C2/C3-endo or C2-exo-unsaturation
within the PBD skeleton (which is
known to improve DNA-binding
affinity and cytotoxicity). For exam-
ple, a difference in cytotoxicity was
observed in comparisons of the
cytotoxicity of SJG-136 (a C2-exo-
unsaturated PBD dimer) with a bis-
alkylating IGN dimer, where the
presence of the D-ring of the IGN
(i.e., replacement of the pyrrolo C-
ring of the PBD with an indolino
moiety) conferred an approxi-
mately 10-fold higher potency in vi-
tro compared to SJG-136.[111] It has also been suggested that
introduction of the D-ring may improve the electrophilicity
and reactivity of the N10–C11 imine functionality through an
electronic effect, although this has not been proven.[112]
A second unique feature of IMGN779 is that, although its
payload is similar in overall format to a standard C8/C8’-
coupled PBD dimer structure, only one of the indolinoben-
zodiazepine moieties contains an electrophilic N10–C11
imine functionality capable of alkylating a guanine base in
the DNA minor groove. The second imine functionality is
reduced to a N10–C11 secondary amine which is non-electro-
philic, and so this indolinobenzodiazepine dimer arrangement
is only capable of mono-alkylating DNA and not cross-
linking. Although IMGN779 is the most clinically advanced
IGN-containing ADC to date (presently in Phase I clinical
trials), it was preceded by studies of an ADC based on a bis-
alkylating payload (i.e., the bis-imine IGN1 dimer, Figure 19)
which was capable of cross-linking DNA.[113]
Figure 19. Structures of the bis-imine indolobenzodiazepine (“IGN”)
payload IGN1, and the isolated DNA-binding component of DGN462.
The bis-imine IGN1 dimer is a symmetrical IGN dimer containing two
electrophilic imines capable of producing DNA cross-links in a similar
manner to standard C8/C8’-linked PBD dimers, whereas the DGN462
payload contains only one imine moiety, with the second reduced to
a non-electrophilic secondary amine. This payload is only capable of
mono-alkylating rather than cross-linking DNA, and so ADCs contain-
ing it may produce less off-target toxicity than IGN1 or other related
cross-linking PBD dimers.[115]
Figure 18. Structure of IMGN779, an indolinobenzodiazepine-based
ADC developed by ImmunoGen Inc. It is distinguished by four unique
structural features: 1) the two additional D-rings attached to the C-
rings of the PBD skeletons (i.e., to create indolobenzodiazepines or
“IGNs”), 2) the conversion of one N10–C11 imine to a non-electro-
philic secondary amine to create a payload that mono-alkylates rather
than cross-links DNA, 3) the central aniline ring within the C8/C8’-
linker to which the antibody is attached, a concept originally developed
by Sanofi, and 4) joining of the DGN462 payload to the antibody via
a cleavable disulfide linker.
Figure 17. Structure of 4D5-PBD, a PBD-containing HER2-neu-targeted ADC developed by Allozyne
Inc. This ADC is unique in the use of click chemistry to form a stable heterocyclic triazole linkage
between azide functionalities engineered into the antibody and an alkyne group at the terminus of
a linker–specifier–PAB–PBD Dimer assembly.
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During the development of IMGN779, three IGN-based
bis-alkylating ADCs were generated (i.e., an anti-EPCAM-
IGN ADC, an anti-CD-33-IGN ADC and an anti-FRa-IGN
ADC) linked through amide bonds to lysine residues within
the antibodies.[109] All three of these ADCs had a DAR of 3
and were attached to the antibody via a non-cleavable linker
requiring lysosomal degradation of the antibody to release
the lysine-linked IGN. These constructs were found to be
highly potent with an antigen-dependent cell-killing effect
and the hindered disulfide linker providing good bystander
killing of proximal cancer cells. For example, the anti-CD-33-
IGN ADC killed cells of the low CD-33 antigen-expressing
leukaemia cell-line NB4 with an IC50 value of 3 pm, whereas
the antigen-negative cell-line Namalwa was > 100-fold less
sensitive to the same ADC. Although these in vitro data were
promising, a troubling pattern started to emerge during
human tumor xenograft studies. Although displaying potent
dose-dependent antitumor activity in a human tumor xeno-
graft of the epidermoid carcinoma KB starting with a single
i.v. dose (activity was observed at concentrations as low as 0.5
mgkg1), the anti-FRa ADC caused prolonged loss in body
weight, and in some cases delayed lethality in non-tumor
bearing CD-1 mice at a dose of 3.75 mgkg1 (qw 3, i.e., once
per week for three weeks). In order to explore the SAR of the
series, the IGN bis-imine dimer was partially reduced to form
a mono-alkylating molecule (i.e., DGN462, Figure 19). Bio-
physical evaluation (e.g., Comet assay and thermal denatura-
tion studies) suggested that the mono-imine and bis-imine
IGNs have different mechanisms of action (i.e., mono-
alkylation and cross-linking), and that the bis-imine molecule
forms a more stable DNA adduct. Remarkably, when the
mono-imine IGN was conjugated to an identical set of
antibodies to the bis-imine IGN to form three new ADCs
(i.e., anti-EPCAM, anti-CD-33 and anti-FRa-ADC), potent
cytotoxicity was observed (i.e., IC50 values of 2–60 pm), and
these ADCs were only 1.3- to 6-fold less potent than the
equivalent bis-imine cross-linking IGN ADCs. Furthermore,
in vivo studies of the anti-FRa mono-imine IGN ADC
produced dose-dependent antitumor activity similar to the
bis-imine IGNADC in the KBmodel, but with ~ 2-fold higher
dosing (i.e., 7.5 mgkg1, qw 3). Non-tumor-bearing CD-
1 mice treated on an identical schedule (i.e., 7.5 mgkg1, qw
3) with the anti-FRa mono-imine IGN ADC showed no
evidence of prolonged or delayed toxicity. The MTD of the
the anti-FRa mono-imine IGN ADC in non-tumor bearing
mice was estimated to be 10 mgkg1. As the minimum
effective dose (MED) was estimated to be 1 mgkg1, this
provided an in vivo therapeutic index of approximately 10.
The design concept of mono-alkylation (i.e., IMGN779)
may have the advantage of producing lower toxicity com-
pared to indolinobenzodiazepines or PBD dimers (e.g., bis-
imine IGN dimers or SG3199) that contain two imine
moieties, as it is now apparent that ADCs containing tradi-
tional PBD dimer payloads that cross-link DNA can lead to
a number of off-target delayed toxicities including bone
marrow suppression.[101]
A third innovation relates to the concept of joining the
indolinobenzodiazepine dimer to the antibody through a cen-
tral aromatic ring within the C8/C8’-linker. In this arrange-
ment, three carbons of the central aromatic ring act as
bioisosteres for the central three methylenes of the C8/C8’-
dioxypentanyl linker found in many traditional PBD dimers.
Finally, the entire ADC construct (IMGN779), which has
a DAR of approximately three, has the indolinobenzodiaze-
pine mono-alkyating dimer joined to the antibody via
a cleavable disulfide linker which is thought to help avoid
some of the toxicities observed with non-cleavable linker
formats.[114] After obtaining positive pre-clinical data, Immu-
noGen has now started a Phase I open-label study of
IMGN779 in patients with relapsed/refractory CD33-positive
AML.
Genentech Inc is also developing PBD dimer based
ADCs, and their method of attaching the PBD payload to the
antibody is similar to that used by Allozyne Inc and
Stemcentrx Inc, involving a self-immolative PAB unit joined
through one of the N10-positions of the PBD dimer
(Figure 20).[116] One example provided in a Genentech
patent consists of a C2/C2’-exo-methylene-substituted PBD
dimer with a C8/C8’-dioxypentamethylene linker (i.e.,
SG2057) joined to a CD79b-targeting antibody (e.g.,
huMA79bv28 or huMA79bv32) to treat lymphomas through
the CD79b antigen found on B-cells.[117] The huMA79bv28 AI
HC antibody, used for proof of concept studies, possesses an
AI-18C mutation in the heavy chain that includes a conjugat-
able thiol group for attachment to the linker-payload
assembly. The payload and antibody were joined through
either Phe–HomoLys (Figure 20A) or Val–Cit (Figure 20B)
specifiers with both connecting to one of the N10-positions of
the PBD dimer via a self-immolative PAB spacer. The Phe-
HomoLys-containing construct (Figure 20A) also included
a polyglycol (i.e., PEG) linker, whereas the Val-Cit-contain-
ing ADC (Figure 20B) had a simple methylene linker.
In vivo studies involving the CD79b ADC shown in
Figure 20B, and the free PBD dimer SG2057 (at an equiv-
alent dose to the ADC itself) were undertaken in which
groups of mice transplanted with CD79b-expressing WSU-
DLCL2 cells were treated with a single intravenous dose of
0.5 or 2.0 mg ADC/kg or 12.9 mgkg1 of free PBD dimer. A
control ADC consisting of an antibody non-specific for the
antigens expressed on WSU-DLCL2 cells was included in the
study. In a 35-day time course study, compared to controls, the
CD79b ADC produced inhibition of tumor growth at the
2.0 mgkg1 dose level with complete responses. Importantly,
growth inhibition was greater than for an ADC based on the
same huMA79bv28 antibody but conjugated to the auristatin
payload MMAE. Interestingly, the PBD dimer (SG2057)
alone did not provide any inhibition of tumor growth under
the same conditions.
Similar constructs to those in Figure 20 but based on anti-
CD33 antibodies have also been patented by Genentech
Inc.[116a] Their efficacy was investigated using mouse xenograft
models based on cell lines of the AML subtypes M2 (HL-60)
and M4a (EOL-1). The animals were first dosed intraper-
itoneally with an excess of an anti-dF control antibody to
ensure non-specific antibody binding sites were blocked.
After this, substantial tumor growth inhibition was observed
in both models after administration of the anti-CD33 ADCs
at both the 1.0 mgkg1 and 20.0 mgm2 dose levels.
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The unsymmetrical PBD dimer approach, initially estab-
lished by ImmunoGen Inc with their mono-alkylating indo-
linobenzodiazepine-containing IMGN779 ADC, has been
adopted by others in the field. For example, Spirogen Ltd
has filed a patent on PBD dimers containing unsymmetrical
C2/C2’-substitution patterns.[118] A number of other PBD-
based ADCs are either in late-stage pre-clinical development
or in early clinical trials, although information is not always
available in the public domain. For example, in 2015 and 2016,
MedImmune/Spirogen announced that it had sub-licensed its
PBD payload technology to Tanabe Research Labs and
Regeneron Inc, respectively, although no details of planned
ADCs were disclosed by either licensee, and other companies
such as Kolltan and Pierre Fabre are also investigating PBD
dimers as ADC payloads. Later stage PBD-containing ADCs
include ADCT-301, developed by ADC Therapeutics Ltd,
which comprises a CD25-targeting antibody (i.e., HuMax-
TAC from Genmab Inc) and a traditional PBD dimer
payload. This conjugate has shown potent dose-dependent
cytotoxicity in CD25-positive cell lines at low doses, with
significant activity against some drug-resistant tumor types. It
entered Phase I clinical trials in early 2015 for the treatment
of lymphoma. ADC Therapeutics is also
developing ADCT-401 which contains
a traditional PBD dimer attached to an
antibody (i.e., J591) targeted to the pros-
tate-specific membrane antigen (PSMA).
Although in vitro and in vivo data have yet
to be disclosed, the conjugate is expected
to enter clinical trials in the near future
with a focus on hormone-refractory pros-
tate cancer. Another analogue, ADCT-402,
has also been disclosed by ADC Thera-
peutics, and has received regulatory appro-
val to enter clinical trials. This ADC
contains a PBD-dimer coupled to a CD19
antibody through a maleimide–Val–Ala
specifier assembly, and in vivo studies
have demonstrated dose-dependent anti-
tumor activity in a human Burkitts lym-
phoma-derived Ramos xenograft model.
For example, a single dose of 0.33 mgkg1
resulted in a significant delay of tumor
growth compared to vehicle treatment
alone, with 4/10 and 10/10 tumor-free
survivors at doses of 0.66 mgkg1 and
1 mgkg1, respectively.[119] Furthermore,
doses of up to 2 mgkg1 were well tolerated
with no adverse side-effects.[119] Recently,
two other ADCs utilizing tesirine have also
been disclosed by ADC Therapeutics. Both
ADCT-502 and ADCT-602 are currently at
the pre-clinical stage. ADCT-502 has been
developed to target HER2-expressing
tumors whereas ADCT-602 is a CD-22
targeting agent. Similarly, efforts are con-
tinuing to explore alternative linking
positions to the C2- and N10-positions for
PBD dimers, and MedImmune/Spirogen
have recently disclosed the use of the C7-position for this
purpose.
Feng and co-workers at the NCI have recently reported
studies involving a PBD-based CD56-targeted ADC.[120]
CD56 is over-expressed in a number of different cancer
types including multiple myeloma, acute myeloid leukaemia
and pancreatic cancer. Using a phage display technique, two
high-affinity anti-CD56 monoclonal antibodies were initially
identified, M900 and M906, that bind to membrane proximal
fibronectin Type III-like domains and the N-terminal IgG-
like domain, respectively. A C2/C2’-bis-aryl-substituted PBD
dimer connected to a MC–Val–Ala linker construct through
the C2-arylamino position was conjugated to both antibodies
with a DAR of 4. The PBD dimer payload was specifically
chosen over other payload families, as many childhood
tumors (especially in children having received prior treat-
ment) are resistant to ADCs containing MMAE and MMAF
payloads.[121] Furthermore, it has been shown that in some
tumors with high multi-drug resistance (e.g., acute myeloid
leukaemia models),[19] PBD dimers can maintain potency. In
the experiments reported to date, the M906-based ADC
produced more potent in vitro activity (i.e., IC50 of 0.05–
Figure 20. Schematic diagram of the PBD-containing CD79b ADC conjugates developed by
Genentech Inc. In these conjugates, the PBD dimer (SG2057) is connected to the antibody–
linker–specifier–PAB assembly through one of its N10-positions in a similar manner to the
ADCs developed by Allozyne Inc and Stemcentrx Inc. The payload SG2057 is similar to SJG-
136 in having C2/C2’-exo-methylene substituents, but differs in that the two PBD units are
connected via a C8/C8’-dioxypentamethylene linker. The two ADC constructs shown above
are similar except that one has a Phe–HomoLys specifier and a PEG-based linker (A),
whereas the other utilizes a Val–Cit specifier and a simple methylene linker (B).
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1.7 pm) compared to the M900 version (i.e., IC50 ~ 100 pm),
and in vivo studies are presently underway.
The first generation of PBD-based ADCs have utilized
G–G cross-linking PBD dimers. However, a recent confer-
ence publication has disclosed that Genentech is actively
investigating PBD-based G–A cross-linkers as potential ADC
payloads.[123] Three types of these molecules have been
reported in the literature to date,[124–126] each comprising
a G-alkylating PBD connected to either a CBI or CI A-
alkylating unit. Denny and co-workers reported[125] an exten-
sive study of PBD–CBI hybrids which contained simple
methylene linkers between the CBI and PBD units
(Figure 21), and these molecules are now being developed
as ADC payloads by Genentech. For example, 27eS, was
found to have a CL50 value of approximately 0.01 mm toward
pcDNA3 plasmid DNA, and an IC50 as low as 0.0078 nm in
some tumor cell lines (i.e., EMT6). The molecule was also
found to have antitumor activity in human tumor xenograft
mouse models. When conjugated to the humanized anti-
HER2 antibody 7C2 (hu7C2) via a disulfide linkage, the
resulting ADC had potent activity in vitro and in vivo, and the
payload alone was found to be a poor substrate for Pgp and
MDR1.[123] AnMTD of 15 mgkg1 (single dose) was observed
in rats for the PBD/CBI-containing ADC, and this compared
favorably to values of < 5 mgkg1 and 10 mgkg1 observed
for the stand-alone CBI dimer (A–A cross-linker) and PBD
dimer payloads, respectively. Both the PBD dimer and PBD–
CBI dimer ADCs contained an identical linker system (i.e.,
disulfide), whereas the CBI dimer was based on a non-
cleavable linker format.
Finally, other companies working on PBD-based ADCs
have focussed on modifications to the central C8/C8’-linker.
For example, Hangzhou DAC Biotech Ltd has patented
a PBD dimer with C2/C2’-exo-methylene substituents and
a thio-oxophosphane moiety at the center of the C8/C8’-
linker (Figure 22A).[127] The thio-ethane substituent on the
central oxophosphane acts as a novel linking point for
antibody attachment. However, another important feature is
that both the N10–C11 and N10’–C11’ imine moieties have
been converted to their sodium bisulfite addition products.
Although this type of modification can produce a prodrug
form of a PBD dimer with significantly enhanced water
solubility, it makes purification more challenging. This
approach was used by Spirogen Ltd to synthesize the PBD
dimer prodrug SG2285 (Figure 22B).[128]
6. Conclusion
It has taken 50 years from the discovery of the first
pyrrolobenzodiazepine (PBD) molecule, anthramycin, by
William Leimgruber in the mid-1960s[2] for the first PBD-
based cancer chemotherapeutic agents to make an impact in
the clinic. In the interim, a vast amount of data on both the
SAR and DNA sequence selectivity of PBDs has been
accumulated, contributing to a broad understanding of their
mechanism of action. Although the PBD dimer SJG-136
reached the clinic as a single agent and is still being evaluated,
the first PBD dimer-based agents to make a clinical impact
have been ADCs containing PBD dimers as chemical pay-
loads (e.g., Seattle Genetics SGN-CD33A,[101] and Stem-
centrxs SC16LD6.5,[110] both of which are now in Phase III
clinical trials). Although anthramycin, sibiromycin and neo-
thramycin were all investigated in previous decades,[5] exam-
ples of PBD monomers have not reached the clinic in recent
years. However, ImmunoGen Inc. has spearheaded a resur-
gence of interest in molecules analogous to PBD monomers
by developing a PBD dimer-type ADC payload (DGN462)
with one active N10–C11 imine functionality disabled (i.e., by
conversion to a non-electrophilic secondary amine) resulting
in an ADC (i.e., IMGN779) which has just entered the
clinic,[115] and this promising technology was sub-licenced by
Takeda in late 2015. Other groups are now developing PBD
monomers as stand-alone anticancer agents (particularly as
transcription factor inhibitors[7,129]), and as antibacterial
agents.[130] A further interesting development, pioneered by
Sanofi S.S. and ImmunoGen Inc, is attachment of the
antibody to a PBD dimer-type payload through a substituted
aromatic ring in the center of the C8/C8’-linker that joins the
two DNA-interactive units together. This has the advantage
Figure 22. Structure of the novel PBD dimer payload patented by
Hangzhou DAC Biotech Ltd[127] (A), and the standalone PBD dimer
SG2285 synthesized by Spirogen Ltd (B). The dimer produced by
Hangzhou contains a central oxophosphane moiety as part of its C8/
C8’-linker, with an appended thio-ethane substituent through which an
antibody can be attached. The molecule has the same C2/C2’-exo-
methylene substitution as SJG-136 but is unique for a PBD ADC
payload in having the N10–C11/N10–C11’ imine functionalities con-
verted to their sodium bisulfite addition products, thus producing
a highly water soluble prodrug form. This prodrug approach was also
used by Spirogen Ltd to produce the highly water soluble PBD dimer
SG2285 shown in B.[123]
Figure 21. Parent structure of the PBD–CBI hybrid dimer series pro-
duced by Denny and co-workers.[122] 27eS (containing a pentamethylene
linker) was found to be most potent, and has been licensed for use as
an ADC payload by Genentech Inc.
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that the PBD and PBD-analog units themselves can have
maximum diversity in their substitution patterns as they do
not have to contain an antibody-linking site.
In conclusion, of the 63 ADCs currently commercialized
or in development, 7 (11%) contain a PBD-based payload,
with auristatin (17, 27%) and maytansine (13, 21%) payloads
used in the majority. However, given the performance of the
PBD dimers as ADC payloads in the clinic to date, and their
structural simplicity and ease of synthesis compared to many
other payload types, it is likely that the percentage of PBD-
containing ADCs will increase significantly in the next
decade, although their wider availability may be restricted
by IP considerations. The concept of potentially reducing
systemic toxicity by using mono-alkylating PBD-type mole-
cules (i.e., IGNs), if proven in the clinic, may enhance the
attractiveness of these molecules as payloads still further.
Overall, the success in the clinic and the current level of
interest in the ADC area shown by pharmaceutical companies
suggests that the ADC field will be a rapid growth area in the
next decade. There are still a number of challenges to
overcome such as widening the therapeutic window[131] and
the optimization of ADCs that work in solid tumor types as
well as haematological cancers, but the success of ado-
trastuzumab emtansine (Kadcyla), and the number of ADCs
targeted to solid tumors currently in development, suggest
that this will be a significant growth area in the future. Also, in
the next decade, the development of novel and more-
sophisticated conjugation strategies and linker systems to
join payloads to antibodies may lead to major improvements
in terms of well-defined DAR values for consistence of
manufacture, improved stability of the final ADC products
and more efficient release of payloads at the tumor site.
Emerging linker technologies also raise the exciting possibil-
ity of attaching different payloads to the same antibody to
improve efficacy. For example, in the case of PBD-based
payloads, combinations with DNA repair or P-gp inhibitors,
or payloads with different mechanisms of action could lead to
improvements in efficacy and reduction in the development
of resistance.
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Pyrrolobenzodiazepines
J. Mantaj, P. J. M. Jackson, K. M. Rahman,
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From Anthramycin to
Pyrrolobenzodiazepine (PBD)-Containing
Antibody–Drug Conjugates (ADCs)
PBDs as payloads for ADCs : The pyrro-
lobenzodiazepines (PBDs) are a family of
DNA-interactive antitumor agents that
bind to guanine bases in the DNA minor
groove in a sequence-selective manner.
They have potent cytotoxicity, and are
being used as payloads for antibody–drug
conjugates (ADCs). This Review outlines
their development from the discovery of
the natural product anthramycin through
to the use of PBD dimer payloads in
ADCs.
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